

AD _____

GRANT NUMBER DAMD17-94-J-4476

TITLE: Network Interaction of erbB, neu-erbB2, erbB3, erbB4,
in the Biological Response to NDF/Heregulins

PRINCIPAL INVESTIGATOR: David F. Stern, Ph.D.

CONTRACTING ORGANIZATION: Yale University School of Medicine
New Haven, Connecticut 06520-8047

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19980408 040

DTIC QUALITY INSPECTED 3

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1997	3. REPORT TYPE AND DATES COVERED Annual (28 Sep 96 - 27 Sep 97)	
4. TITLE AND SUBTITLE Network Interaction of erbB, neu-erbB2, erbB3, erbB4, in the Biological Response to NDF/Heregulins			5. FUNDING NUMBERS DAMD17-94-J-4476	
6. AUTHOR(S) David F. Stern, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Yale University School of Medicine New Haven, Connecticut 06520-8047			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) The gene encoding the neu/erbB-2/HER-2 receptor tyrosine kinase is one of a small number of genes known to be altered in human breast and ovarian carcinoma. It is amplified and/or over expressed in approximately one-fourth of these cancers. With its probable role in etiology, and expression at the cell surface, Neu has great potential as a prognostic indicator and therapeutic target. Efforts to exploit this receptor in the clinical arena have been impeded by the failure to consider regulation of Neu by hormones and co-receptors. This has been complicated by the fact that at least seven different peptide hormones, epidermal growth factor (EGF), transforming growth factor-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, epiregulin, and the diverse neuregulins are all able to activate neu. They work by binding to the co-receptors EGF receptor, erbB-3 and erB-4, which then dimerize with neu. Work by this laboratory has shown that each one of these factors activates a different constellation of receptors, leading to a great diversity of possible response. Moreover, the coupling of cellular responses to each factor is determined by the subset of receptors expressed in each tissue. Thus in order to interpret the function of any one of the factors or receptors, including neu, it is essential to consider the influences provided by the entire set.				
14. SUBJECT TERMS Breast Cancer receptor tyrosine kinase			15. NUMBER OF PAGES 95	
neu/erbB-2/HER-2 oncogene NDF/heregulin			EGF receptor growth factor	
16. PRICE CODE				
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

OL In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

OL In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

OL In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

OL In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

OL
PI - Signature

10/20/97
Date

TABLE OF CONTENTS

Cover	page 1
Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Body	10
Conclusions	13
References	14

INTRODUCTION

Breast cancer is one of the most important cancers afflicting women and presents challenging treatment decisions. After p53 alterations, the most frequent change in an identified gene is amplification and/or overexpression of the *neu/erbB-2/HER-2* gene, which occurs in up to one-third of breast cancers. The gene product (denoted p185 or non-italicized *neu*), is a receptor tyrosine kinase (RTK) ^{1, 2, 3}. This gene was originally discovered in mutant form in chemically-induced rat nervous system tumors and is now known to be a member of the Type 1, or epidermal growth factor (EGF) receptor gene (*erbB*) family. The family includes four receptors, which will be referred to will be referred to herein as the EGFR, *neu*, *erbB-3*, and *erbB-4*. (See our review, ⁴). Small-scale screens for *neu* alterations in human tumors led to discovery of changes in a number of adenocarcinomas including breast ⁵, ovarian, gastric, bladder, lung, and colon. Two influential studies showed that *neu*, and not a panel of other oncogenes is amplified in breast and ovarian carcinomas and that this amplification correlates with RNA and p185 overexpression ^{6, 7}. Numerous studies of *neu* in mammary carcinoma have led to the following conclusions ⁴:

1. *neu* is amplified in 20-30% of mammary carcinomas, with the frequency of amplification higher in tumors from patients with affected lymph nodes ^{8, 9, 10, 11, 12, 13, 14, 15, 16}. The gene amplification suggests that there is a selection in the tumors for *neu* overexpression. (It cannot be absolutely ruled out that neighboring genes are selected for amplification.)

2. Amplification correlates well with concomitant RNA and p185 expression ^{6, 7}. An additional 5% of specimens overexpress the receptor without obvious changes in gene structure or copy number ^{5, 11, 15, 17}.

3. There is no evidence for structural mutations in p185 in human tumors. This negative result is weak owing to the high copy number of genes and the large size of the

mRNA. Recent work in the mouse transgenic system suggests that this issue should be reconsidered ¹⁸.

4. Amplification and/or p185 overexpression can be found in all grades and stages of carcinomas, but not hyperplasia or dysplasia. It is found more frequently in ductal carcinoma in situ (DCIS) than in infiltrating ductal carcinoma (IDC)^{14, 16, 19, 20}.

5. Amplification and/or p185 overexpression is associated with poor prognosis, especially in node-positive patients. However the extent of this association and independence from other prognostic markers varies greatly among different studies (reviewed, ⁴).

Taken together, these data indicate that *neu* amplification and overexpression play a major role in mammary carcinogenesis. This is consistent with findings in model systems: i) the mutated rat *neu* oncogene is as potent as any including *ras* in tissue culture systems. ii) In contrast to other growth factor receptors including the EGFR, overexpression of p185 in the absence of ligand is sufficient to transform cells ^{21, 22}. iii) Transgenic mice harboring a mutationally activated *neu* oncogene develop multi-focal mammary carcinoma when expressed under control of a murine mammary tumor virus (MMTV) promoter, which confers high level expression in mammary gland and a few other tissues (not found in all studies ^{23, 24}. iv) Perhaps most compelling is the fact that transgenic mice carrying a structurally normal *neu* gene driven by the MMTV promoter develop metastatic mammary carcinomas ²⁵. This is noteworthy because it reconstructs what appears to be occurring in human cancer: overexpression of normal p185 in mammary tissue.

Since p185^{*neu*} is a cell surface protein that seems to play a causal role in mammary carcinogenesis, it is under intensive investigation as a therapeutic target ^{4, 26}. Phase II clinical trials, in which patients were infused with anti-*neu* antibody 4D5 have been completed with a roughly 15% response rate, and represent the vanguard for expanded therapeutic trials targeting this receptor (J. Baselga, personal communication). In spite of

the findings linking *neu* to mammary carcinoma, and despite the fact that patients are already being exposed to neu antagonists, little is known about the function of neu either in the organism, or in breast cancer.

The physiological function of p185^{neu}, like any hormone receptor, can only be understood in the context of the hormones that regulate it. The EGFR is activated by binding of at least six different peptide hormones, EGF, TGF- α , amphiregulin (AR), betacellulin (β C), epiregulin²⁷(epi) and heparin-binding EGF-like growth factor (Hb-EGF)^{28, 29, 30, 31}. p185, by itself, cannot bind or be activated by these hormones (epi has not been tested). We discovered that EGF and TGF- α , which do not bind to p185, activate p185 Tyr phosphorylation and stimulate p185-associated kinase activity^{2, 32}. This phenomenon, now termed **transmodulation**, is dependent upon the co-expression of the EGF receptor with p185^{33, 34, 35, 36}. It probably occurs at least in part through formation of receptor heterodimers^{37, 38}. Transmodulation of neu by the EGFR is biologically relevant since it works with EGF, TGF- α , betacellulin (see below) and AR, stoichiometrically activates p185³², permits association of substrates³⁹, and correlates with *in vivo* synergy in transforming ability of these two receptors⁴⁰. Thus wherever the two receptors are co-expressed, EGFR agonists activate *neu*. In cell lines that express both receptors, EGF-regulated neu signaling is at least as important as signaling by the EGFR⁴¹. Since p185 and the EGFR have distinguishable signaling activities⁴², this means that regulation of neu production provides a means to alter the signal coupled to EGF.

The transmodulation of neu by the EGFR is a prototype for other interactions within the Type 1 receptor family discovered more recently. Ignorance of these interactions has confused many groups studying the EGFR and resulted in a rather muddy literature which is just now being rationalized^{4, 43}. For example, several laboratories independently identified an activity termed Heregulin, neu differentiation factor, gp30, p75, neuregulin, ARIA, and Glial Cell Growth Factor (GGF)^{44, 45, 46, 47, 48, 49, 50, 51}, a family of related proteins evidently produced by alternate splicing⁵⁰(They

will be referred to collectively here as NRG, for the composite name neuregulin, or as NDF). At first the NRGs seemed to be *neu* ligands since they activate p185 tyrosine phosphorylation in the absence of the EGFR and could be cross-linked to *neu*^{45, 49}. However, it is now known that NRGs bind to both erbB-3 and erbB-4 which can then activate *neu* by transmodulation^{52, 53}. A further complication of this receptor system is that erbB-3 lacks robust kinase activity, and itself requires a second receptor for activity⁵⁴.

Additional candidates for *neu* ligands have been identified but not yet expressed in recombinant form and tested for activity^{55, 56}. Nonetheless, the independent purification of NRGs by three different laboratories seeking the *neu* ligand suggests that in mammary epithelia the significant inputs to *neu* may come through transmodulation: transmodulating agonists TGF- α , AR, and NDFs are often produced in mammary tissue or cell lines^{57, 58, 59} as are the cooperating receptors. Even if these hormones are uniquely responsible for *neu* activation in mammary tissue, the biological complexities may be enormous. TGF- α and AR, although both EGFR agonists, have somewhat different biological activities²⁸. NRGs at first seemed to have radically different activities than EGF agonists since they promote differentiation in some cell lines^{49, 60} (but not others^{45, 50}), but this has still not been verified in tissue⁴.

In summary, *neu* amplification and overexpression is likely to play a significant role in carcinomas where it occurs. However, the presence of activating mutations and agonistic peptide hormones will regulate *neu* function much more strongly than abundance. The Type 1 RTKs comprise a network in which the signaling potential of each receptor is conditioned not only by the presence of hormones, but is further regulated by the co-expression of related RTKs. The long-term focus of this grant is to define the capabilities of the erbBfamily receptor network: the spectrum of hormones that activate each receptor and receptor combination, and the differences among signalling pathways governed by these receptor systems. These objectives include:

Aim 1: Signalling of individual receptors and receptor combinations will be compared by investigating receptor phosphorylations and substrate phosphorylations to determine how receptor interactions modulate signalling specificity.

Aim 2: Functions of NRG ecto- and endo-domains will be analyzed.

Aim 3: Biological activity of NRGs and NRG/TGF- α combinations will be determined in tissue culture.

BODY

ErbB Receptor Signaling Network

The foremost objective for year 1 (Tasks 1a and 1c) was to determine the ability of each receptor and receptor combination to respond to each of the EGF family agonists. This was done by using stable cell lines produced in year 1 that express erbB, erbB-2, erbB-3, and erbB-4 singly and in all pairwise combinations. In year 1 we completed most of the analysis of the ligands EGF, TGF- α , AR, Betacellulin, NRG, and HbEGF⁶¹. This work was completed in year 2, with publication of 2 additional papers^{62, 63}. In year 2 we undertook analysis of the remaining EGF-related factor described in the original proposal, Cripto-1. Since the goal of this work is a comprehensive analysis of EGF-related factors, we also felt obligated to investigate two factors discovered more recently than the original proposal: epiregulin²⁷, and NRG-2. Work on Cripto-1, NRG-2, and epiregulin is now complete, and has resulted in two publications^{64,65} and one manuscript submitted⁶⁶. Cripto-1 doesn't activate any of the receptors, NRG-2 binds to ErbB-3 and ErbB4, and Epiregulin strongly activates the EGF receptor, but weakly activates ErbB4. Responses of ErbB4 to Betacellulin and to Epiregulin is greatly enhanced in the presence of ErbB-2. This work marks the end of virtually all of Task 1.

Aim 1, Task 2. Mammary Cell Lines. There is mounting evidence that while activation of either EGFR or erbB-2 stimulates mammary cell proliferation and promotes tumorigenesis, increased erbB4 signaling may inhibit proliferation or tumorigenesis by stimulating differentiation. Ectopic treatment of breast tumor cell lines with NRG inhibits their growth and stimulates milk protein synthesis. Moreover, erbB4 overexpression in human mammary tumor samples correlates with markers for a more favorable prognosis, suggesting that erbB4 signaling may inhibit tumorigenicity [Bacus, *et al.*, 1996].

As discussed last year, Task 2 turned out to be not feasible, since MCF-10A cells do not tolerate expression of ErbB-4. We are continuing to approach this problem using the mouse mammary cell line HC11. HC11 cells are a Balb/c mammary cell line cultured

from a mid-pregnant female that can be induced to differentiate and activate milk protein synthesis (β -casein) in the presence of dexamethasone, insulin and PRL (DIP). In order to acquired DIP responsiveness, HC11 cells must first become "competent" through confluent incubation in the presence of EGF. However, EGF actually suppresses induction of β -casein by DIP. This latter response is mediated by Stat5. In contrast to EGF, mutationally activated ErbB-2 induces competence, but has no inhibitory effect on β -casein. Finally, NRG resembles EGF in inducing competency, and inhibiting β -casein production, and inducing production of a 22kd milk protein in the presence of DIP. These EGF-like properties and failure to induce full differentiation by NRG contrast with results of pellet implant experiments. Although there are numerous differences between the in vitro and in vivo situations, there may be a simple explanation. We have found that HC11 cells express EGFR, ErbB-2, and ErbB-3, but do not produce ErbB-4 mRNA detectable by RNase protection. We hypothesize that introduction of ErbB-4 into these cells will convert the NRG response to a differentiation response, and are currently testing these idea as an alternative approach to Task 2.

II.NRG Intracellular Domain

The cytoplasmic domain of NRG family EGF-related growth factors is unusual in showing extraordinary diversity of regulation by splicing, and in that some forms have unusually long cytoplasmic tails of unknown function (over 400 amino acids). We hypothesize that these tails are likely to themselves transmit signals so that binding of NRG ecto-domains to the cognate receptors results in bidirectional signaling.

Task 3b. The major focus of work on the NRG intracellular domain has been to develop physical and two-hybrids screens to identify binding partners. In order to screen for a broad range of potential interactors, we are using a cDNA library made from a 12-13 day whole murine fetus. We have produced two baits, *GAL4*-BD- exon 11, and -exons 11+12+13, and verified expression by immunoblotting with anti-Gal4. With 4.2×10^6 clones screened), 6 positives have completed the the screen. The second bait has yielded

75 positives in the first round only, and we are currently working through the remainder of this screen. Once these two screens are completed, we will identify one or two best-guess candidates for further analysis, and use reconstruction experiments and other means to determine their validity. We anticipate that this work will identify truly novel functions for these intracellular domain peptides.

Glutathione-S-transferase (GST)-fusion proteins. A complementary method for identification of interacting proteins is affinity purification. This has the advantage of using full-length cellular proteins, that are expressed in their native environment, but probably requires stabler interactions than two-hybrids screening. We are using glutathione agarose affinity purification to identify proteins that bind specifically to GST-fusions of NRG cytoplasmic segments. Once positives are identified, this approach can be used for purification for direct sequencing, to verify positives identified in two-hybrids screens, and/or to verify positives from solid phase screening (see below).

GST fusion proteins have been produced with GST-coding sequences fused to the three intracellular exons. These fusion proteins express well, and are being used currently in pilot "pull-down" and Far-Western experiments to identify potential interactors. In preliminary experiments, the three GST-fusions isolate different bands in pull-down experiments with 35S-Met/Cys-labeled extracts from a mammary carcinoma cell line. This approach does not lead directly to molecular clones, but may identify candidates with deduced identities. For Far-Western experiments, the fusion proteins will be labeled in vitro by phosphorylation with cAMP-dependent protein kinase catalytic subunit, since the GST-tag (in pGEX2TK) also includes a phosphorylation site. This probe will be used to identify specific bands in blots. Ideally, GST-affinity purification will identify the same proteins as revealed by Far-western analysis, helping to confirm both results. If the results are clean, the next step will be to use the same probes in screens of cDNA expression libraries.

CONCLUSIONS

In year 3, we finally completed our comprehensive analysis of interactions of ErbB family receptors with their ligands⁶⁷. This work, provides a resource that will benefit all investigators working in the EGF receptor family. This work has resulted in four new published or submitted papers. The definition of the abilities of individual EGF-related hormones to regulate specific receptors and receptor combinations is absolutely essential for understanding the biology of any of these hormones and their receptors and is a significant contribution of this work. This "wiring diagram" will benefit all investigators working in the system and is a unique contribution of our laboratory. Moreover, since we have determined that ErbB-4 may antagonize mammary proliferation, our ability to predict which hormones directly activate ErbB-4 may have clinical significance.

We are now investigating the use of a rodent model, HC11 cells, for pinpointing the connection between ErbB family receptors and mammary epithelial response. This will provide an important in vitro system that will be integrated with transgenic work we are performing to address the role of these receptors in normal mammary epithelium. Results from these model systems will be important in explaining how normal cellular responses coupled to these receptors go awry in breast cancer.

Finally, we have completed most of the ground-work for elucidating the function of the NRG tail, and nearly completed the two-hybrids screens. This work will lead to identification of new signaling functions for these ligands, that will be important in understanding their role in mammary tissue and other locales in which NRGs function.

REFERENCES

1. Bargmann, C. I., Hung, M. C., and Weinberg, R. A.: The *neu* oncogene encodes an epidermal growth factor receptor-related protein. *Nature* 1986, 310:226-230
2. Stern, D. F., Heffernan, P. A., and Weinberg, R. A.: p185, a product of the *neu* proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. *Mol. Cell. Biol.* 1986, 6:1729-1740
3. Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with *neu* oncogene. *Science* 1985, 230:1132-1139
4. Hynes, N. E., and Stern, D. F.: The biology of *erbB-2/neu/HER-2* and its role in cancer. *Biochimica et Biophysica Acta Reviews on Cancer* 1994, 1198:165-184
5. King, C. R., Swain, S. M., Porter, L., Steinberg, S. M., Lippman, M. E., and Gelmann, E. P.: Heterogeneous expression of *erbB-2* messenger RNA in human breast cancer. *Cancer Res.* 1989, 49:4185-4191
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L.: Human breast cancer: correlation of relapse and survival with amplification of the *HER-2/neu* oncogene. *Science* 1987, 235:177-182
7. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F.: Studies of the *HER-2/neu* proto-oncogene in human breast and ovarian cancer. *Science* 1989, 244:707-712
8. Ali, I. U., Campbell, G., Lidereau, R., and Callahan, R.: Amplification of *c-erbB-2* and aggressive human breast tumors? *Science* 1988, 240:1795-1796
9. Anbazhagan, R., Gelber, R. D., Bettelheim, R., Goldhirsch, A., and Gusterson, B. A.: Association of *c-erbB-2* expression and S-phase fraction in the prognosis of node positive breast cancer. *Ann. Oncol.* 1991, 2:47-53
10. Gasparini, G., Gullick, W. J., Bevilacqua, P., Sainsbury, R. C., Meli, S., Boracchi, P., Testolin, A., La Malfa, G., and Pozza, F.: Human breast cancer: prognostic significance of the *c-erbB-2* oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. *J. Clin. Oncol.* 1992, 10:686-695
11. Hynes, N. E.: Amplification and overexpression of the *erbB-2* gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. *Sem. in Cancer Biol.* 1993, 4:19-26
12. Kallioniemi, O.-P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L.-C., Smith, H. S., Waldman, F. M., Pinkel, D., and Gray, J. W.: *ERBB2* amplification in breast cancer analyzed by fluorescence *in situ* hybridization. *Proc. Natl. Acad. Sci. USA* 1992, 89:5321-5325

13. Levine, M. N., and Andrulis, I.: The Her-2/*neu* oncogene in breast cancer: so what is new? *J. Clin. Oncol.* 1992, 10:1034-1036
14. van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R.: *Neu*-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. *N. Engl. J. Med.* 1988, 319:1239-1245
15. Clark, G. M., and McGuire, W. L.: Follow-up study of HER-2/*neu* amplification in primary breast cancer. *Cancer Res.* 1991, 51:944-948
16. Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C., and McGuire, W. L.: Overexpression of HER-2/*neu* and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. *Hum. Pathol.* 1992, 23:974-979
17. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R.: Overexpression of the EGF receptor-related proto-oncogene *erbB-2* in human mammary tumor cell lines by different molecular mechanisms. *EMBO* 1987, 6:605-610
18. Siegel, P. M., Dankort, D. L., Hardy, W. R., and Muller, W. J.: Novel activating mutations in the *neu* proto-oncogene involved in induction of mammary tumors. *Molecular and Cellular Biology* 1994, 14:7068-7077
19. Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H. G., Lees, A. W., Jamil, N., Hanson, J., Jenkins, H., Krause, B. E., McBlain, W. A., Slamon, D. J., and Fourney, R. M.: Correlation between *c-erbB-2* amplification and risk of recurrent disease in node-negative breast cancer. *Cancer Res.* 1991, 51:556-567
20. Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., and King, C. R.: Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of *erbB-2* protein overexpression in primary breast cancer. *J. Clin. Oncol.* 1990, 8:103-112
21. Hudziak, R. M., Schlessinger, J., and Ullrich, A.: Increased expression of the putative growth factor receptor p185^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA* 1987, 84:7159-7163
22. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A.: *erbB-2* is a potent oncogene when overexpressed in NIH/3T3 cells. *Science* 1987, 237:178-182
23. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P.: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated *c-neu* oncogene. *Cell* 1988, 54:105-115

24. Bouchard, L., Lamarre, L., Tremblay, P. J., and Jolicoeur, P.: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/*c-neu* oncogene. *Cell* 1989, 57:931-936
25. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J.: Expression of the *neu* protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proceedings of the National Academy of Sciences USA* 1992, 89:10578-10582
26. Baselga, J., and Mendelsohn, J.: Receptor blockade with monoclonal antibodies as anti-cancer therapy. *Pharmac. Ther.* 1994, 64:127-154
27. Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K.: Epiregulin: A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. *Journal of Biological Chemistry* 1995, 270:7495-7500
28. Plowman, G. D., Green, J. M., McDonald, V. L., Neubauer, M. G., Distèche, C. M., Todaro, G. J., and Shoyab, M.: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. *Mol. Cell. Biol.* 1990, 10:1969-1981
29. Shing, Y., Christofori, G., Hanahan, D., Ono, Y., Sasada, R., Igarashi, K., and Folkman, J.: Betacellulin: a mitogen from pancreatic beta cell tumors. *Science* 1993, 259:1604-1607
30. Derynck, R.: The physiology of transforming growth factor- α . *Adv. Cancer Res.* 1992, 58:27-52
31. Higashiyama, S., Abraham, J. A., Miller, J., Fiddes, J. C., and Klagsbrun, M.: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. *Science* 251:936-939. *Science* 1991, 251:936-939
32. Stern, D. F., and Kamps, M. P.: EGF-stimulated tyrosine phosphorylation of p185^{*neu*}: a potential model for receptor interactions. *EMBO Journal* 1988, 7:995-1001
33. Connelly, P. A., and Stern, D. F.: The epidermal growth factor receptor and the product of the *neu* protooncogene are members of a receptor tyrosine phosphorylation cascade. *Proc. Natl. Acad. Sci. USA* 1990, 87:6054-6057
34. King, C. R., Borrello, I., Bellot, F., Comoglio, P., and Schlessinger, J.: EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the *erbB-2* protein in the mammary tumor cell line SK-BR-3. *EMBO* 1988, 7:1647-1651
35. Johnson, G., Kannan, B., Shoyab, M., and Stromberg, K.: Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185^{*erbB2*}. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells. *J. Biol. Chem.* 1993, 268:2294-2931

36. Spivak-Kroizman, T., Rotin, D., Pinchasi, D., Ullrich, A., Schlessinger, J., and Lax, I.: Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. *J. Biol. Chem.* 1992, 267:8056-8063
37. Goldman, R., Ben Levy, R., Peles, E., and Yarden, Y.: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. *Biochem.* 1990, 29:11024-11028
38. Wada, T., Qian, X., and Greene, M. I.: Intermolecular association of the p185^{neu} protein and EGF receptor modulates EGF receptor function. *Cell* 1990, 61:1339-1347
39. Peles, E., Ben-Levy, R., Tzahar, E., Liu, N., Wen, D., and Yarden, Y.: Cell-type specific interaction of Neu differentiation factor (NDF/hergulin) with Neu/HER-2 suggests compoex ligand-receptor relationships. *EMBO Journal* 1993, 12:961-971
40. Kokai, Y., Meyers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., and Greene, M. I.: Synergistic interaction of p185 c-*neu* and the EGF receptor leads to transformation of rodent fibroblasts. *Cell* 1989, 58:287-292
41. Graus-Porta, D., Beerli, R. R., and Hynes, N. E.: Single-chain antibody-mediated intracellular retention of erbB-2 impairs neu differentiation factor and epidermal growth factor signaling. *Molecular and Cellular Biology* 1995, 15:1182-1191
42. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H.: EGF receptor and *erbB*-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. *Science* 1990, 248:79-83
43. Earp, J. S., Dawson, T. L., Li, X., and Yu, H.: Heterodimerization and functional interaction between EGF receptro family members: A new signaling paradigm with implications for breast cancer research. *Breast Cancer Research and Treatment* 1995, 35:115-132
44. Lemke, G.: Recitative and aria. *Nature* 1993, 362:291-292
45. Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Shepard, H. M., Kuang, W.-J., Wood, W. I., Goeddel, D. V., and Vandlen, R. L.: Identification of heregulin, a specific activator of p185^{erbB2}. *Science* 1992, 256:1205-1210
46. Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., and Lippman, M. E.: Direct interaction of a ligand for the *erbB*2 oncogene product with the EGF receptor and p185^{erbB2}. *Science* 1990, 249:1552-1555
47. Lupu, R., Colomer, R., Kannan, B., and Lippman, M. E.: Characterization of a growth factor that binds exclusively to the *erbB*-2 receptor and induces cellular responses. *Proc. Natl. Acad. Sci. USA* 1992, 89:2287-2291

48. Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Ben Levy, R., and Yarden, Y.: Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. *Cell* 1992, 69:205-216
49. Wen, D., Peles, E., Cupples, R., Suggs, S. V., Bacus, S. S., Luo, Y., Trail, G., Hu, S., Silbiger, S. M., Levy, R. B., Koski, R. A., Lu, H. S., and Yarden, Y.: Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. *Cell* 1992, 69:559-572
50. Marchionni, M. A., Goodearl, A. D. J., Chen, M. S., Bermingham-McDonogh, O., Kirk, C., Hendricks, M., Danehy, F., Misumi, D., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Hsuan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P., and Gwynne, D.: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. *Nature* 1993, 362:312-318
51. Corfas, G., Falls, D. L., and Fischbach, G. D.: ARIA, a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185kDa muscle transmembrane *protein*. *Proc. Natl. Acad. Sci. USA* 1993, 90:1624-1628
52. Plowman, G., Green, J., Culouscou, J.-M., Carlton, G., Rothwell, V., and Buckley, S.: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. *Nature* 1993, 366:473-475
53. Sliwkowski, M., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. *Journal of Biological Chemistry* 1994, 269:14661-14665
54. Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., and K L Carraway, I.: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. *Proceedings of the National Academy of Sciences USA* 1994, 91:8132-8136
55. Huang, S. S., and Huang, J. S.: Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney. *J. Biol. Chem.* 1992, 267:11508-11512
56. Dobashi, K., Davis, J. G., Mikami, Y., Freeman, J. K., Hamuro, J., and Greene, M. I.: Characterization of a neu/c-erbB-2 protein-specific activating factor. *Proc. Natl. Acad. Sci. USA* 1991, 88:8582-8586
57. Normanno, N., Qi, C.-F., Gullick, W. J., Persico, G., Yarden, Y., Wen, D., Plowman, G., Kenney, N., Johnson, G., Kim, N., Brandt, R., Martinez-Lacaci, I., Dickson, R. B., and Salomon, D. S.: Expression of amphiregulin, cripto-1, and heregulin α in human breast cancer cells. *Int. J. Oncol.* 1993, 2:903-911
58. Liscia, D. S., Merlo, G., Ciardiello, F., Kim, N., Smith, G. H., Callahan, R., and Salomon, D. S.: Transforming Growth Factor- α Messenger RNA Localization in the

Developing Adult Rat and Human Mammary Gland by in Situ Hybridization. *Developmental Biology* 1990, 140:123-131

59. LeJeune, S., Leek, R., Horak, E., Plowman, G., Greenall, M., and Harris, A. L.: Amphiregulin, Epidermal Growth Factor Receptor, and Estrogen Receptor Expression in Human Primary Breast Cancer. *Cancer Research* 1993, 53:3597-3602
60. Culouscou, J.-M., Plowman, G. D., Carlton, G. W., Green, J. M., and Shoyab, M.: Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180^{erbB4} receptor. *J. Biol. Chem.* 1993, 268:18407-18410
61. Riese II, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C., and Stern, D. F.: Cellular response to neuregulins is governed by complex interactions of the erbB receptor family. *Mol. Cell. Biol.* 1995, 15:5770-5776
62. Riese II, D. J., Bermingham, Y., van Raaij, T. M., Buckley, S., Plowman, G. D., and Stern, D. F.: Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin- β . *Oncogene* 1996, 12:345-353
63. Riese II, D., Kim, E., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, G. D., and Stern, D. F.: The epidermal growth factor receptor couples transforming growth factor alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. *Journal of Biological Chemistry* 1996, 271:20047-20052
64. Chang, H., Riese II, D.J., Gilbert, W., Stern, D.F., and U.J. McMahan. 1997. Ligands for ErbB family receptors encoded by a newly characterized neuregulin-like gene. *Nature*: 387: 509-512.
65. Kannan, S., DeSantis, M., Lohmeyer, M., Riese II, D.J., Smith, G.H., Hynes, N., Seno, M., Brandt, R., Bianco, C., Persico, G., Kenney, N., Normanno, N., Martinez-Lacaci, I., Ciardello, F., Stern, D.F., Gullick, W.J., Salomon, D.S. 1997. Cripto enhances the tyrosine phosphorylation of Shc and activates MAP kinase in mammary epithelial cells. *J. Biol. Chem.* 272: 3330-3335.
66. Riese, II, D.J., Komurasaki, T., Plowman, G.D., and Stern, D.F. Activation of ErbB4 by the bifunctional EGF family hormone epiregulin is regulated by ErbB2. *submitted for publication.*
67. Riese II, D.J., and Stern, D.F. Specificity Within the EGF Family/ErbB Receptor Family Signaling Network. 1998. *BioEssays in press.*

APPENDIX

new publications from the grant from the current project period

- Kannan, S., DeSantis, M., Lohmeyer, M., Riese II, D.J., Smith, G.H., Hynes, N., Seno, M., Brandt, R., Bianco, C., Persico, G., Kenney, N., Normanno, N., Martinez-Lacaci, I., Ciardello, F., **Stern**, D.F., Gullick, W.J., Salomon, D.S. 1997. Cripto enhances the tyrosine phosphorylation of Shc and activates MAP kinase in mammary epithelial cells. *J. Biol. Chem.* 272: 3330-3335.
- Chang, H., Riese II, D.J., Gilbert, W., **Stern**, D.F., and U.J. McMahan. 1997. Ligands for ErbB family receptors encoded by a newly characterized neuregulin-like gene. *Nature*: 387: 509-512.
- Riese II, D.J., and **Stern**, D.F. Specificity Within the EGF Family/ErbB Receptor Family Signaling Network. 1998. *BioEssays in press*.
- Riese, II, D.J., Komurasaki, T., Plowman, G.D., and **Stern**, D.F. Activation of ErbB4 by the bifunctional EGF family hormone epiregulin is regulated by ErbB2. *submitted for publication*.

Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells*

(Received for publication, June 19, 1996, and in revised form, November 7, 1996)

Subha Kannan,^a Marta De Santis,^a Matthias Lohmeyer,^b David J. Riese II,^{c,d}
Gilbert H. Smith,^a Nancy Hynes,^e Masaharu Seno,^a Ralf Brandt,^a Caterina Bianco,^a
Graziella Persico,^f Nicholas Kenney,^g Nicola Normanno,^h Isabel Martinez-Lacaci,^{a,i}
Fortunato Ciardiello,^j David F. Stern,^c William J. Gullick,^b and David S. Salomon^{a,k}

From the ^aTumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, NIC, National Institutes of Health, Bethesda, Maryland 20892, the ^bICRF Oncology Unit, Hammersmith Hospital, London, United Kingdom, the ^cDepartment of Pathology, BML-350, Yale University School of Medicine, New Haven, Connecticut 06520-8023, the ^dFriedrich Meischer-Institut, CH-4002 Basel, Switzerland, the ^eIstituto Internazionale di Genetica e Biofisica, Naples, Italy, the ^fVincent T. Lombardi Cancer Research Center, Georgetown University, Washington, D. C. 20007, the ^gOncologia Sperimentale d'Istituto Nazionale Per lo Studio e La Cura, Dei Tumori-Fondazione Pascale, Naples, Italy, and the ^hCattedra di Oncologia Medica, II Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli Federico II, 80131 Naples, Italy

Cripto-1 (CR-1), a recently discovered protein of the epidermal growth factor (EGF) family, was found to interact with a high affinity, saturable binding site(s) on HC-11 mouse mammary epithelial cells and on several different human breast cancer cell lines. This receptor exhibits specificity for CR-1, since other EGF-related peptides including EGF, transforming growth factor α , heparin-binding EGF-like growth factor, amphiregulin, epiregulin, betacellulin, or heregulin β 1 that bind to either the EGF receptor or to other type 1 receptor tyrosine kinases such as *erb* B-3 or *erb* B-4 fail to compete for binding. Conversely, CR-1 was found not to directly bind to or to activate the tyrosine kinases associated with the EGFR, *erb* B-2, *erb* B-3, or *erb* B-4 either alone or in various pairwise combinations which have been ectopically expressed in Ba/F3 mouse pro-B lymphocyte cells. However, exogenous CR-1 could induce an increase in the tyrosine phosphorylation of 185- and 120-kDa proteins and a rapid (within 3–5 min) increase in the tyrosine phosphorylation of the SH2-containing adaptor proteins p66, p52, and p46 Shc in mouse mammary HC-11 epithelial cells and in human MDA-MB-453 and SKBr-3 breast cancer cells. CR-1 was also found to promote an increase in the association of the adaptor Grb2-guanine nucleotide exchange factor-mouse *son of sevenless* (mSOS) signaling complex with tyrosine-phosphorylated Shc in HC-11 cells. Finally, CR-1 was able to increase p42^{erk-2} mitogen-activated protein kinase (MAPK) activity in HC-11 cells within 5–10 min of treat-

ment. These data demonstrate that CR-1 can function through a receptor which activates intracellular components in the *ras/raf/MEK/MAPK* pathway.

The human *cripto-1* (CR-1)¹ gene (also known as *teratocarcinoma-derived growth factor-1* (TDGF-1)) is located on chromosome 3p21.3 and codes for a 28–36-kDa glycoprotein of 188 amino acids. CR-1 possesses an epidermal growth factor (EGF)-like consensus sequence that contains six cysteine residues in a region of approximately 37 amino acids (1). However, unlike other peptides within this family of growth factors that have a three-looped EGF-motif (designated A, B, and C) which are formed by three intramolecular disulfide bonds, the EGF-like repeat in CR-1 lacks an A loop and the B loop is truncated (2, 3). In addition, unlike most growth factors in the EGF family, the human CR-1 protein lacks a conventional hydrophobic signal peptide and a classical hydrophobic transmembrane domain (2). Nevertheless, recombinant human CR-1 protein is secreted when transiently expressed in Chinese hamster ovary cells (3). Refolded CR-1 peptides that correspond to the EGF-like repeat within the human CR-1 protein are mitogenic for nontransformed and malignant human and mouse mammary epithelial cells (3). Human CR-1 can also function as a dominant transforming gene *in vitro* in mouse NIH-3T3 fibroblasts and in mouse NOG-8 mammary epithelial cells (1, 4). CR-1 mRNA and immunoreactive CR-1 protein are differentially expressed in several human breast cancer cell lines, in approximately 80% of primary human infiltrating breast tumors and in 50% of ductal carcinomas *in situ* (5, 6).

Peptide growth factors that are members of the EGF family include transforming growth factor α (TGF α), amphiregulin (AR), heparin-binding EGF-like growth factor, betacellulin (BTC), epiregulin, and the neuregulin subfamily that consists

* This work was supported in part by the National Cancer Institute, United States Public Health Service Grant CA-45708, and United States Army Medical Research and Material Command Grant DAMD-17-94-J-4476 (to D. F. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^a Supported by the National Cancer Institute, United States Public Health Service Grant HD-07149, and United States Army Medical Research and Material Command Grant DAMD-17-94-J-4036.

ⁱ Supported by the United States Army Medical Research and Material Command Grant DAMD-17-94-J-4498.

^k To whom all correspondence and reprint requests should be addressed: Bldg. 10, Rm. 5B39, Tumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, NCI, National Institutes of Health, Bethesda, MD 20892. Tel.: 301-496-9536; Fax: 301-402-8656; E-mail: davetgfa@helix.nih.gov.

¹ The abbreviations used are: CR-1, *cripto-1*; EGF, epidermal growth factor; TGF α , transforming growth factor α ; AR, amphiregulin; HRG, heregulin; BTC, betacellulin; EGFR, EGF receptor; mSOS, mouse *Son of Sevenless*, guanine nucleotide exchange factor; MAPK, mitogen-activated protein kinase; *erk*, extracellular signal-regulated protein kinase; MEK, mitogen-activated *erk*-activating kinase; MBP, myelin basic protein; Shc, *Src* homologous and collagen protein; Grb2, growth factor receptor-bound protein; PAGE, polyacrylamide gel electrophoresis; Tricine, *N*-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.

of various isoforms of α and β heregulin (HRG), glial cell growth factors, and acetylcholine receptor inducing activity (7–10). The different neuregulins are derived by alternative splicing from a single gene. Peptides in the EGF family bind to and activate members of the *erb* B family of type 1 receptor tyrosine kinases. EGF, TGF α , AR, heparin-binding EGF-like growth factor, and epiregulin bind exclusively to the epidermal growth factor receptor (*erb* B/EGFR), whereas the neuregulin subfamily of peptides bind to *c-erb* B-3/HER-3 or *c-erb* B-4/HER-4 that can then heterodimerize and activate *c-erb* B-2/HER-2 following transphosphorylation (11–15). BTC can bind to either the EGFR or *c-erb* B-4. Since ligand-dependent activation of the EGF receptor can also lead to heterodimerization with *c-erb* B-2, *c-erb* B-3, or *c-erb* B-4, this suggests that different pairs of heterodimers within the type 1 receptor tyrosine kinase family may contribute to the array of responses to various EGF-like ligands in a cell-specific and possibly ligand-specific manner by the recruitment of different combinations of intracellular signaling proteins (14). This apparent redundancy of different ligands and receptors may therefore contribute to signal diversification and amplification. One major pathway that is activated by a several different EGF-like ligands through these type 1 receptor tyrosine kinases is the *ras/raf/mitogen*-activated protein kinase (MAPK) signal transduction pathway (16).

The HC-11 mouse mammary epithelial cell line is a clonal isolate originally derived from the COMMA-1D cell line, which was established from a midpregnant Balb/c mouse mammary gland (17). These cells express a number of mammary epithelial markers such as β -casein and express several distinct type 1 receptor tyrosine kinases, including the EGFR, *c-erb* B-2, and *c-erb* B-3 (17–20). In this context, HC-11 cells have been useful as an *in vitro* model system in which to define the intracellular signaling pathways that are engaged by EGF-related peptides that utilize these type 1 receptor tyrosine kinases and are involved in regulating proliferation and differentiation in mammary epithelial cells (19, 20). In the present study, we have attempted to define the intracellular signaling pathway that might be activated in HC-11 cells and in several different human breast cancer cell lines by a 47-mer refolded CR-1 peptide that corresponds in sequence to the EGF-like repeat of the human CR-1 protein (3). The CR-1 related peptide was found to bind to a unique specific, high-affinity receptor that is not the EGFR, *erb* B-2, *erb* B-3, or *erb* B-4. CR-1 was also found to enhance the tyrosine phosphorylation of the SH2-adaptor protein, Shc, and to promote the association of Grb2-mSOS intracellular signaling complex with tyrosine-phosphorylated Shc. These events were subsequently related to the downstream activation of the p42^{erk-2} MAPK isoform.

MATERIALS AND METHODS

Cell Culture and Growth—HC-11 mouse mammary epithelial cells were routinely grown in RPMI 1640 medium containing 8% heat-inactivated fetal bovine serum, 5 μ g/ml bovine insulin (Sigma), and 10 ng/ml EGF (Collaborative Research, Watham, MA). Human breast cancer cell lines, MCF-7, ZR-75-1, T-47D, MDA-MB-231, MDA-MB-453, and SKBr-3 were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and insulin (10 μ g/ml) as described previously (21). The Ba/F3 mouse pro-B lymphocyte cell line and clonal derivatives that express individual or pairs of type 1 receptor tyrosine kinases were generated as described previously (22, 23). Cells were treated with different concentrations of either refolded p47 CR-1 peptide that corresponds in sequence to the EGF-like motif in human CR-1 (3), recombinant human TGF α (Bachem), recombinant human AR, recombinant human HB-EGF, recombinant human BTC (R & D Systems, Inc.), recombinant mouse epiregulin (generously supplied by Toshi Komuraski, Taisho Pharmaceutical Co., Saitama, Japan), or recombinant human HRG β 1_{177–244} (generously supplied by Mark Sliwkowski, Genentech, Inc., South San Francisco, CA).

Immunoprecipitation and Western Blot Analysis—Cells were grown

until they were subconfluent and then propagated in serum-free medium containing human transferrin (10 μ g/ml) and type 1V Pedersen fetuin (1 mg/ml) for 48 h. Cells were treated in serum-free medium with different concentrations of p47 CR-1 for various times and then lysed in 20 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 5 mM MgCl₂, 2 μ g/ml aprotinin, 2 μ g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 20 mM sodium fluoride. In some cases the clarified protein lysates were either immunoprecipitated (0.5 mg/sample) with 2 μ g of a rabbit anti-Shc antibody (Transduction Laboratories, Lexington, KY) or with 2 μ g of anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Biotechnology, Inc.). Crude protein lysates (25 μ g/sample) or immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, blocked with 2% dry milk in Tris-buffered saline with 0.05% Tween 20, and incubated with a 1:1000 dilution of anti-Shc, anti-Grb-2, or anti-mSOS monoclonal antibodies (Transduction Laboratories) or a 1:2000 dilution of the anti-phosphotyrosine monoclonal antibodies 4G10 and/or PY-20 (ICN Pharmaceuticals, Inc., Costa Mesa, CA). The bound mouse monoclonal antibodies were detected using a 1:5000 dilution of goat anti-mouse IgG conjugated to horseradish peroxidase (Amersham). Immunoreactive bands were detected by enhanced chemiluminescence (ECL, Amersham). *erb* B receptors were immunoprecipitated from recombinant Ba/F3 clonal derivatives using monospecific antisera as described previously (22).

MAPK Assays—A rabbit anti-MAPK antibody (Upstate Biotechnology, Inc., Lake Placid, NY) at a 1:1000 dilution that recognizes both extracellular signal-regulated protein kinase *erk-1* and *erk-2* MAPK was used to detect activation of immunoreactive MAPK proteins by means of band shift following SDS-PAGE of crude cellular lysates as described previously (24). Bands were detected by the colorimetric NBT/BCIP system (Kirkegaard Perry Labs, Gaithersburg, MD). Alternatively, cells were lysed in buffer containing 1% Nonidet P-40, 0.5% deoxycholate, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM sodium orthovanadate, 2 μ g/ml leupeptin, 2 μ g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride. Lysates (100 μ g/sample) were immunoprecipitated with an anti-*erk-1* rabbit antibody (Santa Cruz Biotechnology, Santa Cruz, CA). After 2 h, the immunoprecipitates were washed twice with lysis buffer followed by a final wash in kinase buffer containing 30 mM HEPES (pH 7.4), 10 mM MgCl₂, 10 mM MnCl₂, and 1 mM dithiothreitol. After the final wash, the immunoprecipitates were suspended in 30 μ l of kinase buffer containing 5 μ g of myelin basic protein (MBP) and 5 μ Ci of [γ -³²P]ATP (1000 Ci/mmol, Amersham) and incubated for 30 min at 37 °C. The reaction was stopped with 2 $\times$ SDS sample buffer. The samples were then run on a 10% Tricine gel followed by autoradiography. The MBP bands were quantified with a densitometer (Molecular Dynamics) (19).

Ligand Binding Assays—¹²⁵I-p47 CR-1 peptide was prepared using IODO-GEN (Pierce Chemical Co.) in which 5 μ g of peptide was labeled with 1 mCi of Na¹²⁵I to a specific activity of 5–10 μ Ci/ μ g. Monolayers of HC-11 cells or human breast cancer cells in 12-well cluster dishes were washed in serum-free RPMI 1640 or Dulbecco's modified Eagle's medium containing 20 mM HEPES (pH 7.4) and 0.1% bovine serum albumin and treated in the same medium. Cells were incubated at 23 °C for 2 h in 1 ml of binding buffer containing 3 $\times$ 10⁵ cpm of ¹²⁵I-p47 CR-1 in the absence or presence of increasing concentrations of unlabeled p47 CR-1 or with other EGF-related peptides. Cells were washed twice with phosphate-buffered saline and then solubilized in 1 ml of buffer containing 10 mM Tris-HCl (pH 8.0) and 0.5% SDS and counted in a γ -counter. The binding data were analyzed using the Ligand program to determine the *K_d* value as described (25).

RESULTS

Binding of CR-1 to HC-11 Mouse Mammary Epithelial Cells and Human Breast Cancer Cells—A 47-mer CR-1 refolded peptide that contains the EGF-like motif of human CR-1 is able to stimulate the proliferation and to inhibit β -casein expression in mouse HC-11 mammary epithelial cells.² To determine if a high-affinity, specific binding site is expressed on HC-11 mammary epithelial cells that might mediate the biological effects of CR-1, HC-11 cells were incubated with ¹²⁵I-p47 CR-1 in the absence or presence of increasing concentrations of unlabeled p47 CR-1. As illustrated in Fig. 1A, there is specific binding of the ¹²⁵I-p47 CR-1 peptide to HC-11 cells with a *K_d* of approxi-

² S. Kannan, manuscript in preparation.




FIG. 1. Binding and competition curve of ^{125}I -p47 CR-1. Binding of ^{125}I -p47 CR-1 to HC-11 cells (A); *insert*, Scatchard plot of binding isotherm. B, competition of specific binding of ^{125}I -p47 CR-1 to HC-11 cells by various concentrations of EGF ($\circ$), AR ($\square$), TGF α ($\blacksquare$), HRG β 1 ($\blacktriangle$), or p47 CR-1 ($\bullet$). C, MDA-MB-231 human breast cancer cells were treated with 25 $\mu\text{g}/\text{ml}$ anti-EGFR monoclonal antibody or 25 $\mu\text{g}/\text{ml}$ anti-erb B-2 TAB 250 monoclonal antibody and specific binding of ^{125}I -p47 CR-1 (10 ng/ml) was determined.

mately 96 nM (Fig. 1A, *insert*). Various concentrations of EGF, TGF α , AR, or HRG β 1 were unable to compete for binding with ^{125}I -p47 CR-1 on HC-11 cells (Fig. 1B). Likewise, heparin-

TABLE I
Characteristics of CR-1 binding to mouse and human mammary epithelial cells

Data were obtained from appropriate Scatchard plots using various concentrations of unlabeled p47 CR-1 with ^{125}I -p47 CR-1.

Cell line	nM	Sites/cell
HC-11	96	3.9×10^5
MDA-MB-453	80	4.4×10^5
MDA-MB-231	33	1.8×10^5
SKBr 3	78	4.5×10^5
ZR-75-1	61	1.1×10^5
T47-D	50	1.4×10^5
MCF-7	26	5.3×10^4

binding EGF-like growth factor, epiregulin, or BTC were ineffective in blocking the binding of the ^{125}I -p47 CR-1 peptide (data not shown). This potential receptor is not unique to HC-11 mouse mammary epithelial cells since ^{125}I -p47 CR-1 also binds specifically and with high affinity to several estrogen receptor positive (MCF-7, T47-D, and ZR-75-1) and to estrogen receptor negative (MDA-MB-231, MDA-MB-453 and SKBr-3) human breast cancer cell lines that exhibits comparable specificity for CR-1 binding as in mouse HC-11 cells (Table I). Moreover, blocking the EGFR receptor on MDA-MB-231 human breast cancer cells with 25 $\mu\text{g}/\text{ml}$ of the 528 anti-EGFR monoclonal blocking antibody which is sufficient to impede ^{125}I -EGF binding (26) does not lead to any change in the specific binding of ^{125}I -p47 CR-1 to these cells (Fig. 1C), confirming the observation that CR-1 does not directly bind to the EGFR (3). In addition, the binding of ^{125}I -p47 CR-1 peptide to MDA-MB-231 cells or SKBr-3 cells (data not shown) is unaffected by the anti-erb B-2 TAB 250 blocking monoclonal antibody.

CR-1 Fails to Directly Activate erb B Family Receptor Tyrosine Phosphorylation in Recombinant Ba/F3 Cells—Parental Ba/F3 mouse pro-B lymphocytes express low levels of endogenous erb B-3 but do not express EGFR, erb B-2, or erb B-4. Ba/F3 clones have been genetically engineered to ectopically express either EGFR, erb B-2, erb B-3, or erb B-4 type 1 receptor tyrosine kinases either alone or in different pairwise combinations (22, 23). These recombinant cell lines have been particularly useful in defining different homodimeric and heterodimeric combinations of the type 1 receptor tyrosine kinases that can bind to various ligands within the EGF family of peptides (23). Since CR-1 is structurally related in part to this family of peptides, the 47-mer CR-1 refolded peptide and an Sf9-derived recombinant human GST-CR-1 fusion protein³ were tested for their ability to directly bind and stimulate receptor tyrosine phosphorylation in single recombinant Ba/F3 derivatives that are expressing different erb B family members (Fig. 2). p47 CR-1 was unable to significantly modify EGFR (Fig. 2A), erb B-2/neu/HER-2 (Fig. 2B), erb B-3/HER-3 (Fig. 2D), or erb B-4/HER-4 (Fig. 2C) tyrosine phosphorylation in Ba/F3 clones that were expressing these tyrosine kinases. In contrast, BTC was able to stimulate EGFR and erb B-4 phosphorylation (Fig. 2, A and C) while HRG β 1 was able to indirectly stimulate erb B-2 phosphorylation (Fig. 2B) by binding to endogenous erb B-3 (22). p47 CR-1 was also ineffective in modulating the tyrosine phosphorylation of these different type 1 receptor tyrosine kinases in Ba/F3 cells that were expressing different pairs of erb B receptors demonstrating that CR-1 does not directly bind to heterodimers within this family of receptor tyrosine kinases (data not shown). Similar negative results on tyrosine receptor phosphorylation in either single or double erb B expressing recombinant Ba/F3 clones were obtained after treatment of

³ M. Seno, manuscript in preparation.




FIG. 2. Modulation of *erbB* receptor tyrosine phosphorylation by CR-1 in recombinant Ba/F3 clonal derivatives. Ba/F3 clones that were expressing individual *erbB* family members including the EGFR (A), *erbB-2* (B), *erbB-4* (C), or *erbB-3* (D) were treated without (lane 1 in A–D) or with 100 ng/ml p47 CR-1 (lane 3 in A–C or lane 2 in D), BTC (lane 2 in A and C), or HRG β 1 (lane 2 in B) for 10 min. Cell lysates were then immunoprecipitated with monospecific anti-receptor antibodies and analyzed by immunoblotting with anti-phosphotyrosine antibodies.

these cells with the full-length Sf9 recombinant GST-human CR-1 fusion protein.

CR-1 Stimulates Tyrosine Phosphorylation of Shc and Activates MAPK in HC-11 Mammary Epithelial Cells and in Human Breast Cancer Cells.—Although CR-1 does not directly activate any known type 1 receptor *erbB* tyrosine kinase, its receptor may still consist of a membrane-associated tyrosine kinase or alternatively the receptor may associate with another cytoplasmic or membrane bound tyrosine kinase to generate a signal. To determine if the p47 CR-1 peptide could modulate the tyrosine phosphorylation of other proteins in HC-11 cells, serum-starved cells were treated with p47 CR-1 for 5 min and cell lysates were immunoprecipitated with 4G10 mouse monoclonal anti-phosphotyrosine antibody. Immunoprecipitates were then electrophoresed and probed by Western blot analysis with the PY-20 mouse monoclonal anti-phosphotyrosine antibody (Fig. 3A). An increase in tyrosine phosphorylation of a 185-kDa protein was observed. A similar CR-1-induced increase in the tyrosine phosphorylation of a 185-kDa protein was also observed in other cells that were capable of binding ^{125} I-p47 CR-1 such as MDA-MB-453, SKBr3, and T47-D human breast cancer cells after immunoprecipitation and Western blotting with anti-phosphotyrosine antibodies (data not shown). The identity of the p185 phosphoprotein has not yet been identified.

Shc is an SH-2 containing adaptor protein that exists as three distinct isoforms of 66, 52, and 46 kDa and that becomes tyrosine-phosphorylated after ligand activation of several different type 1 receptor tyrosine kinases (27–29). Cell lysates from p47 CR-1-treated serum-starved HC-11 cells exhibited a time-dependent increase in the tyrosine phosphorylation of the p66 Shc and p46 Shc isoforms, which could be detected following immunoprecipitation with an anti-Shc antibody and subse-

quent screening in Western blot analysis with anti-phosphotyrosine antibodies (Fig. 3, B and C). In HC-11 cells which had been sufficiently serum-starved, the increase in phosphorylation of p46 Shc (Fig. 3B) and p66 Shc (Fig. 3C) in response to p47 CR-1 was transient with an 8-fold increase in p46 Shc phosphorylation being observed after 5–7 min, which decreased to control levels after 10 min of treatment (Figs. 3B and 5B). No significant changes in the phosphorylation of the p52 isoform of Shc were detected in HC-11 cells. A less dramatic but measurable increase in the tyrosine phosphorylation of either p52 and/or p46 Shc could also be detected in either MDA-MB-453 or SKBr-3 human breast cancer cells after treatment with either the p47 CR-1 peptide (Fig. 3C) or the GST-CR-1 recombinant fusion protein (data not shown). Proteins of 185 and 120 kDa that were also tyrosine-phosphorylated in a transient manner were detected in the Shc immunoprecipitates after probing the Western blots with a mixture of two different anti-phosphotyrosine monoclonal antibodies (Fig. 3C). These proteins were found to co-immunoprecipitate with Shc after stimulation of HC-11, MDA-MB-453, or SKBr-3 cells with p47 CR-1. The identity of these two proteins has not been determined.

Shc is an adaptor protein that can bind to specific consensus sequences which contain phosphotyrosine residues in the COOH terminus of several different tyrosine kinase receptors through either an SH2 domain or a phosphotyrosine-binding domain (29). In turn, binding of phosphorylated Shc to the SH2 domain of Grb2 through the tyrosine-phosphorylated collagen homology domain of Shc can link a number of different growth factor receptor tyrosine kinases to the *ras/raf/MEK/MAPK* signaling pathway since Grb2 is intrinsically complexed with the *ras* guanine nucleotide exchanger, SOS (27, 29). To ascertain if p47 CR-1 could facilitate the association of the Grb2-mSOS complex with phosphorylated Shc in mammary epithelial cells, HC-11 cell lysates were immunoprecipitated with the Shc antibody and immunoblotted with either an anti-Grb2 (Fig. 4A) or an anti-SOS (Fig. 4B) antibody. In both cases, p47 CR-1 induced a time-dependent increase in the association of Grb2 and mSOS with phosphorylated Shc. Activation of p21^{ras} by SOS can ultimately lead to the downstream activation of mitogen-activated, *erk*-activating kinase (MEK) through *raf* and the subsequent stimulation of MAPK activity (16, 30). To ascertain if p47 CR-1 could stimulate MAPK activity, serum-starved HC-11 cells were treated for different times with the peptide, and cell lysates were electrophoresed and probed with an anti-MAPK antibody that detects both MAPK isoforms, p44^{erk-1} and p42^{erk-2} (Fig. 5A). Alternatively, cell lysates were immunoprecipitated with an anti-MAPK antibody and utilized in an *in vitro* kinase assay with MBP as a substrate to quantify total MAPK activity (Fig. 5B). The p47 CR-1 peptide produced a rapid tyrosine phosphorylation of p42^{erk-2} within 3–5 min that could be detected by the presence of a slower migrating band that represents the phosphorylated form of p42^{erk-2} (Fig. 5A). Phosphorylation of this species of p42^{erk-2} peaked at 7 min and subsequently declined. A nearly 4-fold increase in phosphorylation of the MAPK substrate, MBP, was also observed and found to have identical kinetics in response to p47 CR-1 treatment and was delayed relative to the increase in p46 Shc phosphorylation (Fig. 5B).

DISCUSSION

EGF, TGF α , AR, and HRG β 1 stimulate the growth and regulate the differentiation of normal and malignant mouse and human mammary epithelial cells *in vitro* (7, 11, 31–34). However, the role of other EGF-related peptides in regulating the growth and differentiation of mammary epithelial cells has not been fully explored. This may be particularly important since only a subset of peptides within the EGF family bind exclu-




FIG. 3. Tyrosine phosphorylation of Shc after CR-1 treatment. Serum-starved HC-11 (A-C) or MDA-MB-453 or SKBr-3 human breast cancer cells (C) were treated without or with 100 ng/ml p47 CR-1 for 5 min. A, lane 2, or various times indicated (B and C). The cell lysates were immunoprecipitated with anti-phosphotyrosine (4G10, Upstate Biotechnologies) antibody (A) or a polyclonal anti-Shc antibody (B and C). The immunoprecipitates (IP) were resolved on a 8–16% SDS-PAGE gel and immunoblotted with a PY20 antibody (A and B, upper panel) or a mixture of PY20 and 4G10 antibodies (C). The lower panels in B and C represent the same blots stripped and reprobed with monoclonal anti-Shc antibody to demonstrate that equal amounts of Shc are present in all lanes.




FIG. 4. Enhanced Grb2-mSOS association with Shc upon CR-1 stimulation in HC-11 cells. HC-11 cells were treated without or with p47 CR-1 (100 ng/ml) for various times. The cell lysates were immunoprecipitated (IP) with polyclonal anti-Shc antibody and analyzed by Western blotting using an anti-Grb2 (A) or anti-mSOS (B) antibody.

sively to the EGFR. Additional proteins in this family, such as the neuregulin subfamily which include the HRGs, bind to other members of the type 1 receptor tyrosine kinase family of receptors such as *c-erb* B-3 or *c-erb* B-4, that can then heterodimerize and activate *c-erb* B-2 following transphosphorylation (3–15, 31, 34–36). Finally, BTC can equally activate either the EGFR or *c-erb* B-4 (23). Since ligand-dependent activation of the EGF receptor can also lead to heterodimerization with *c-erb* B-2, *c-erb* B-3, or *c-erb* B-4, this suggests that different combinatorial pairs of heterodimers within the type 1 receptor tyrosine kinase family may contribute in a hierarchical fashion through signal diversification to the array of responses that are produced to various EGF-like ligands in a

cell-specific manner (14, 15, 35, 36).

The present study is the first to demonstrate that a refolded peptide which corresponds in sequence to the EGF-like motif of the human CR-1 protein can bind to a unique receptor that can modify the tyrosine phosphorylation of different proteins which are components in the *ras/raf/MEK/MAPK* pathway. CR-1 is a newly discovered member of the EGF family of peptides that is structurally unique within this family as CR-1 lacks an A loop and possesses a truncated B loop (2, 3, 7). Since conserved amino acid residues in the A loop in conjunction with residues in the C loop are necessary for peptide binding to the EGFR receptor (37) and since the 47-mer refolded CR-1 related peptide does not directly compete with EGF for binding to the EGFR (3), this demonstrates that CR-1 cannot bind to this receptor. Nevertheless, CR-1 is able to stimulate the proliferation and differentiation of HC-11 cells² and the growth of several different nontransformed human mammary epithelial and breast cancer cell lines suggesting that a receptor exists for this peptide (3). In this context, the synthetic CR-1 peptide interacts with a high-affinity binding site on HC-11 mouse mammary epithelial cells and on several different human breast cancer cell lines that exhibit specificity for the CR-1 47-mer peptide since other EGF-related peptides that bind either to the EGFR or *c-erb* B-3 and *c-erb* B-4 fail to compete for binding with the labeled p47 CR-1 peptide. This suggests that the CR-1-binding site is unique. Conversely, the CR-1 peptide or recombinant GST-CR-1 fusion protein does not directly activate the tyrosine kinase of either the EGFR or other members of the type 1 receptor tyrosine kinase family either alone or in various heterodimeric combinations in mouse Ba/F3 cells (22, 23). Nevertheless, the ability of 47-mer CR-1 peptide to induce the tyrosine phosphorylation of 185- and 120-kDa proteins in HC-11 mouse mammary epithelial cells and MDA-MB-453 or SKBr-3 human breast cancer cells suggests that CR-1 binds to a potential receptor that has either an intrinsic tyrosine kinase




FIG. 5. Effect of CR-1 on MAPK activation in HC-11 cells. HC-11 cells were treated for various times with p47 CR-1 (100 ng/ml). In **A** crude cell lysates were run on 10% SDS-PAGE gels and probed with an anti-MAPK antibody (Santa Cruz) to show the hyperphosphorylated, slower migrating band of p42^{erk-2}. In **B**, insert, cell lysates were immunoprecipitated with anti-erk-2 antibody (Upstate Biotechnology) and assayed for MAPK activity by an *in vitro* kinase assay using MBP as a substrate followed by electrophoresis and autoradiography. Blots **B** in 3 and 5 were scanned densitometrically using NIH Image program 1.58 and the phosphorylation of Shc (■) and MAPK (□) relative to control are represented graphically.

activity or that associates with a tyrosine kinase. In this context, it is known that various members of the type 1 receptor tyrosine kinase family can heterodimerize following ligand binding or associate with p60^{c-src}. Heterodimerization might facilitate the activation of different signaling proteins thereby contributing to signal amplification and diversification in response to different type 1 receptor ligands (14, 15, 36). The present experiments do not formally exclude the possibility that the CR-1 receptor can also heterodimerize with one of these type 1 receptor tyrosine kinases or with other soluble src-related tyrosine kinases and that these interactions may be essential for propagation of an intracellular signal.

The present data also demonstrates that p47 CR-1 treatment of HC-11, MDA-MB-453, or SKBr-3 cells can lead to a rapid increase in tyrosine phosphorylation of the p66, p52, and p46 isoforms of Shc which can then associate with the Grb2-mSOS signaling complex. Since this is one possible mechanism by which other growth factor receptor tyrosine kinases can couple to the MEK/MAPK pathway through *ras* and *raf* (27–30, 38), these results may be functionally significant with respect to defining components in the intracellular signal transduction pathway that are activated by the CR-1 receptor. Moreover, the results demonstrate that CR-1 can activate p42^{erk-2} MAPK by rapidly inducing the tyrosine phosphorylation of this MAPK isoform. Since activation of MAPK by various growth factors appears in certain cells to be obligatory for cell proliferation and/or for differentiation (16), then this same situation may also be applicable to CR-1 in its ability to stimulate growth and modulate the expression of β -casein and whey acidic protein in HC-11 cells and in primary mouse mammary epithelial cells in response to lactogenic hormones such as prolactin.² Identification and characterization of the CR-1 receptor following chemical cross-linking of its ligand should clarify some of these

issues. In this respect, attempts to chemically cross-link the ¹²⁵I-p47 CR-1 peptide have been unsuccessful. However, we have recently expressed a full-length, refolded, biologically active human CR-1 protein in *Escherichia coli* and in Sf9 insect cells with a baculovirus expression vector.³ Cross-linking of these proteins to appropriate target cells such as HC-11 should now be feasible.

REFERENCES

- Ciccodicola, A., Dono, R., Obici, S., Simeone, A., Zollo, M., and Persico, M. G. (1989) *EMBO J.* **8**, 1987–1991
- Dono, R., Montuori, N., Rocchi, M., De Ponti-Zilli, L., Ciccodicola, A., and Persico, M. G. (1991) *Am. J. Hum. Genet.* **49**, 555–565
- Brandt, R., Normanno, N., Gullick, W. J., Lin, J.-H., Harkins, R., Schneider, D., Jones, B.-W., Ciardiello, F., Persico, M. G., Armenante, F., Kim, N., and Salomon, D. S. (1994) *J. Biol. Chem.* **269**, 17320–17328
- Ciardiello, F., Dono, R., Kim, N., Persico, M. G., and Salomon, D. S. (1991) *Cancer Res.* **51**, 1051–1054
- Qi, C.-F., Liscia, D. S., Normanno, N., Merlo, G., Johnson, G. R., Gullick, W. J., Ciardiello, F., Saeki, T., Brandt, R., Kim, N., Kenney, N., and Salomon, D. S. (1994) *Br. J. Cancer* **69**, 903–910
- Dublin, E. A., Bobrow, L. G., Barnes, D. M., and Gullick, W. J. (1995) *Int. J. Oncol.* **7**, 617–622
- Normanno, N., Ciardiello, F., Brandt, R., and Salomon, D. S. (1994) *Breast Cancer Res. Treat.* **29**, 11–27
- Mudge, A. W. (1993) *Curr. Biol.* **3**, 361–364
- Watanabe, T., Shintani, A., Nakata, M., Shing, Y., Folkman, J., Igarashi, K., and Sasada, R. (1994) *J. Biol. Chem.* **269**, 9966–9973
- Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K. (1995) *J. Biol. Chem.* **270**, 7495–7500
- Karunakaran, D., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. (1995) *J. Biol. Chem.* **270**, 9982–9990
- Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S. K. (1996) *J. Biol. Chem.* **271**, 3884–3890
- Cohen B. D., Green, J. M., Foy, L., and Fell H. P. (1996) *J. Biol. Chem.* **271**, 4813–4818
- Pinkas-Kramarski, R., Soussan, L., Waterman, Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Seala, M., and Yarden, Y. (1996) *EMBO J.* **15**, 2452–2467
- Beerli, R. R., and Hynes, N. E. (1996) *J. Biol. Chem.* **271**, 6071–6076
- Marshall, C. J. (1995) *Cell* **80**, 179–185
- Hynes, N. E., Taverna, D., Harwerth, I. M., Ciardiello, F., Salomon, D. S., Yamamoto, T., and Groner, B. (1990) *Mol. Cell. Biol.* **10**, 4027–4034
- Taverna, D., Groner, B., and Hynes, N. E. (1991) *Cell Growth Differ.* **2**, 145–154
- Marte, B. M., Graus-Porta, D., Jeschke, M., Fabbro, D., Hynes, N. E., and Taverna, D. (1995) *Oncogene* **10**, 167–175
- Marte, B. M., Jeschke, M., Graus-Porta, D., Taverna, D., Hofer, P., Groner, B., Yarden, Y., and Hynes, N. E. (1995) *Mol. Endocrinol.* **9**, 14–23
- Normanno, N., Qi, C.-F., Gullick, W. J., Persico, G., Yarden, Y., Wen, D., Plowman, G., Kenney, N., Johnson, G., Kim, N., Brandt, R., Martinez-Lacaci, I., Dickson, R. B., and Salomon, D. S. (1993) *Int. J. Oncol.* **2**, 903–911
- Riese, D. J., Van Raaij, T. M., Plowman, G. D., Andrews, G. C., and Stern, D. F. (1995) *Mol. Cell. Biol.* **15**, 5770–5776
- Riese, D. J., Berminham, Y., Van Raaij, T. M., Buckley, S., Plowman, G. D., and Stern, D. F. (1996) *Oncogene* **12**, 345–353
- Ray, L. B., and Sturgill, T. W. (1988) *Proc. Natl. Acad. Sci. U. S. A.* **85**, 3753–3757
- Munson, P. J., and Rodbard, D. (1980) *Anal. Biochem.* **107**, 220–239
- Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., and Mendelsohn, J. (1993) *J. Natl. Cancer Inst.* **85**, 1327–1333
- Pellicci, G., Lanfrancone, L., Salcini, A. E., Romano, A., Mele, S., Borrello, M. G., Segatto, O., Di Fiore, P. P., and Pellicci, P. G. (1995) *Oncogene* **11**, 899–907
- Ravichandran, K. S., Lorenz, U., Shoelson, S. E., and Burakoff, S. J. (1995) *Mol. Cell. Biol.* **15**, 593–600
- Batzer, A. G., Blaikie, P., Nelson, K., Schlessinger, J., and Margolis, B. (1995) *Mol. Cell. Biol.* **15**, 4403–4409
- Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) *J. Biol. Chem.* **269**, 32621–32625
- Peles, E., and Yarden, Y. (1993) *BioEssays* **15**, 815–824
- Lin, C. Q., Dempsey, P. J., Coffey, R. J., and Bissell, M. J. (1995) *J. Cell Biol.* **129**, 1115–1126
- Yang, Y., Spitzer, E., Meyer, D., Sachs, M., Niemann, C., Hartmann, G., Weidner, K. M., Birchmeier, C., and Birchmeier, W. (1995) *J. Cell Biol.* **131**, 215–226
- Normanno, N., Selvam, M. P., Qi, C.-F., Saeki, T., Johnson, G., Kim, N., Ciardiello, F., Shoyab, M., Plowman, G., Brandt, R., Todaro, G., and Salomon, D. S. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91**, 2790–2794
- Carraway, K. L., and Cantley, L. C. (1994) *Cell* **78**, 5–8
- Earp, H. S., Dawson, T. L., Li, X., and Yu, H. (1995) *Breast Cancer Res. Treat.* **35**, 115–132
- Groenen, L. C., Nice, E. C., and Burgess, A. W. (1994) *Growth Factors* **11**, 235–257
- Quilliam, L. A., Khosravi-Far, R., Huff, S. Y., and Der, C. J. (1995) *BioEssays* **17**, 395–404

Ligands for ErbB-family receptors encoded by a neuregulin-like gene

Han Chang*, David J. Riese II†, Walter Gilbert‡, David F. Stern§ & U. J. McMahan*

* Department of Neurobiology, Stanford University School of Medicine, Stanford, California 94305-5401, USA

Departments of † Pathology, § Pathology and Biology, Yale University School of Medicine, New Haven, Connecticut 06340, USA

‡ Department of Molecular and Cellular Biology, Harvard University, 16 Divinity Avenue, Cambridge, Massachusetts 02138, USA

Neuregulins (also called ARIA¹, GGF², heregulin³ or NDF⁴) are a group of polypeptide factors that arise from alternative RNA splicing of a single gene. Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissues⁵⁻⁷. Here we report the cloning of a second neuregulin-like gene, neuregulin-2. The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor (EGF)-like domain gives rise to two isoforms (α and β). Northern blot and *in situ* hybridization analysis of adult rat tissues indicate that expression of neuregulin-2 is highest in the cerebellum, and the expression pattern is different from that of neuregulins. Recombinant neuregulin-2 β induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell lines expressing all of these ErbB-family receptors. However, in cell lines with defined combinations of ErbBs, neuregulin-2 β only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.

ErbB2, ErbB3 and ErbB4⁸⁻¹⁰ are members of a subfamily of receptor tyrosine kinases that also includes the EGF receptor (EGFR). Signalling through ErbB family receptors is important for regulating cell proliferation and differentiation in many tissues⁵⁻⁷, and deregulation of these signalling pathways is implicated in a variety of cancers¹¹. Although it has been demonstrated that neuregulins can activate ErbB2/3/4 receptors through direct or indirect interaction^{12,13}, additional ligands for ErbB-family receptors may exist¹⁴⁻¹⁶. We used a polymerase chain reaction (PCR) based strategy to search for neuregulin-related sequences in an adult rat cerebellum complementary DNA library and have identified a new neuregulin-like gene¹⁷, neuregulin-2.

Figure 1 shows the deduced amino-acid sequence of neuregulin-2 β , derived from a composite of two overlapping cDNA clones. This composite contains an open reading frame (ORF) encoding a 754-amino-acid protein. Sequence analysis revealed four structural motifs: a putative signal sequence, a C2-type immunoglobulin-like (Ig-like) domain¹⁸, an EGF-like domain (residues 252-297) with its six characteristic cysteines¹⁹, and a putative transmembrane domain (which separates the whole sequence into a 315-residue extracellular domain and a 414-residue cytoplasmic domain). Another neuregulin-2 cDNA clone, with an extra 77-base-pair (bp) exon inserted between the fourth and fifth cysteine residues of the EGF-like domain, encodes an alternatively spliced variant of neuregulin-2 with a different EGF-like domain (see Supplementary Information). This neuregulin-2 isoform also lacks a transmembrane domain, because the insertion of the extra exon causes a frameshift in the downstream sequence and the termination of the ORF 33 amino acids downstream of the EGF-like domain. Neuregulin-2 molecules having two variant EGF-like domains are termed neuregulin-2 α and neuregulin-2 β , respectively. The neuregulin

gene also has a similar alternative splicing site that gives rise to the α - and β -subtypes of neuregulins^{2,3,20}, although neuregulin-2 α and neuregulin-2 β are about equally distant from neuregulin- α or from neuregulin- β . Moreover, there is another alternative splicing site in the cytoplasmic domain of neuregulin-2 in other neuregulin-2 cDNA clones (data not shown), corresponding to the a/b/c-tail splicing site in the neuregulin gene²⁰. Therefore, neuregulin-2 and neuregulin not only have similar sequences, they also have similar gene structures.

A protein-database search revealed that the neuregulin-2 proteins are most similar to neuregulins (and to heregulin- β 1 among the isoforms of the neuregulins). Overall neuregulin-2 β shares 45% identity with heregulin- β 1 (ref. 3) and 40% with GGFII (ref. 2). Apart from the N terminus of neuregulin-2 β , the similarity between neuregulin-2 β and heregulin- β 1 extends through their entire sequence (Fig. 2). On the other hand, the N terminus of neuregulin-2 β has significant identity to that of GGFII (43%) (Fig. 2). The

```

1  MRRDPAPGFSMLLFGVSLACYSFSLKSVQDQAYKAPVVEGKVGQGLAPAGSSSSNSTREP  60
61  PASGRVALVKVLDKWLRSGLQREQVIVSGSCAPLERNQRYIFFLEPTEQPLVFKTAF  120
121 PVDPNGKNIKKEVGKILCTDCATRPKLKKMSQTEVGEGKQSLKCEAAGNPQPSYRWF  180
181 DGKELNRSRDIRIKYGNCRKNSRLQFNKVKVEDAGEYVCEAENILGKDTVGRHLHNSVS  240
241 TTLSSWSGHAKCNETAKSYCVNGGVCCYIEGINQLSCKCPVGYTGDRCCQFAMVNSKH  300
301 LGFELKEAEELYQKRVLTITGICVALLVGVIVCVVAYCKTKKQRRQMHHLRQNMCPAHQ  360
361 NRSLANGPSPHRLDPEEIQMADYISKNPATDHVIRREAETTFSSGSHSCSPSHHCSTATP  420
421 TSSHRHESHTWSLSESLTSDSGIMLSSVGTSKCNSPACVEARRAAAYSQEERRR  480
481 AAMPFYHSDISLDRSPHSERYVSALTTPARLSPVDFHYSLATQVPTFEITSPNSAHAVS  540
541 LPPAAPISYRLAEQQPLLRLHAPPGPFGPGADMQRSDSYYYPAAGPGRGACALGGS  600
601 LGSLPASPFHIPEDDEYETTQECAPPPPPRPRTRGASRRTSAGPRRWRRLNGLAAQRA  660
661 RAARDSLSLSSGSGSASASDDDDADDGALAESTPFLGLRAAHDLRSDSPPLCPAA  720
721 DSRTYYLDSHSTRASSRHSRGPPTRAKQDSGLP  754
  
```

Figure 1 Deduced amino-acid sequence of rat neuregulin-2 β . Arrowed underline marks the putative signal sequence. The immunoglobulin-like domain is outlined by a dashed box. Solid frame surrounds the EGF-like domain; the six cysteines characteristic of this domain are indicated by asterisks. Potential N-glycosylation sites are marked with arrowheads. The putative transmembrane region is underlined. An arrow points to the potential proteolytic site.




Figure 2 The motif structure of the neuregulin-2 β and its similarity to selected members of neuregulins. The percentage similarity is calculated from the amino-acid sequence alignment of neuregulin-2 β , heregulin- β 1 (human)³ and the N terminus of GGFII (human)². Black boxes, potential signal sequences; Ig, immunoglobulin-like domains; EGF, EGF-like domains; TM, transmembrane domains.

most similar region between neuregulin-2 β and heregulin- β 1 is the transmembrane domain (91% identity) and adjacent sequence. Highly conserved regions also exist in the cytoplasmic tails of neuregulin-2 β and heregulin- β 1, indicating that the cytoplasmic domains may be important biologically. Relatively high conserva-

tion between neuregulin cytoplasmic tails from distant vertebrate species has been noted before¹. As the EGF-like domain of neuregulins is sufficient for receptor binding and for stimulating cellular responses³, we compared the EGF-like domain of neuregulin-2 molecules with other EGF-like motifs. Among the known EGF-like motifs, the EGF-like domain of neuregulin-2 is most similar to that of the neuregulins (48% identity between terminal cysteines in the case of heregulin- β 1). Second to neuregulins is the rat epidermal growth factor, with 43% identity between terminal cysteines.

To determine the size and tissue distribution of neuregulin-2 mRNAs, northern blot hybridization with poly(A)⁺ RNA was carried out using a probe spanning the EGF-like domain plus the immunoglobulin-like domain (Fig. 3A). Among the adult rat tissues examined, neuregulin-2 transcripts were most abundant in neural tissues (brain and spinal cord) and lung. A separate experiment with total RNA samples shows that the cerebellum has the highest concentration of neuregulin-2 transcripts compared to other parts of the brain and other adult tissues (data not shown). Three bands were seen in brain samples (Fig. 3A): a prominent band of 3 kilobases (kb), and two additional bands of 3.8 and 6 kb. Only the 3- and 3.8-kb transcripts were detected in spinal cord and lung samples. This pattern of three principal transcripts has also been found for the neuregulin gene, but at the sensitivity of the northern blot, the tissue distribution of neuregulin-2 transcripts in adult rat seems to be more restricted than that of neuregulins^{3,4}.

We also characterized neuregulin-2 expression by *in situ* hybridization with several probes. In adult rat brain sections, the highest expression was detected in the cerebellum (in the Purkinje cell layer and the granule cell layer) and in the dentate gyrus of the hippocampus (Fig. 3B). Labelled cells were also found in the olfactory bulb (data not shown). This expression pattern seems to be distinct from that of neuregulins, because no hybridization signal for neuregulins is observed in Purkinje cells and very little in the granule cell layer²¹. We investigated the expression pattern of




Figure 3 Expression of neuregulin-2 transcripts in adult rat tissues. **A**, Northern blot analysis using poly(A)⁺ RNA samples; approximately 2 μ g poly(A)⁺ RNA was loaded in each lane. The three bands detected (3, 3.8, 6 kb) are indicated. Lv, liver; L, lung; M, skeletal muscle; B, brain; Sc, spinal cord; **B**, *In situ* hybridization of adult rat brain parasagittal sections with a digoxigenin-labelled cRNA probe spanning the EGF-like and Ig domains. **a**, Neuregulin-2 transcripts were detected in Purkinje cells (P) and in the granule cell layer (gcl) in the cerebellum, but not in the molecular cell layer (mcl); scale bar, 0.4 mm. **b**, Adjacent section hybridized with a sense control probe. **c**, In the hippocampus, neuregulin-2 transcripts were only detected in the dentate gyrus (DG) but not in the CA1-CA3 area; scale bar, 0.8 mm. **d**, Adjacent section hybridized with the sense control probe.




Figure 4 Recombinant neuregulin-2 β protein induces tyrosine-phosphorylation of ErbB-family receptors through ErbB3 and ErbB4. **a**, Neuregulin-2 β induces tyrosine phosphorylation of ErbB2, ErbB3 and ErbB4 in MDA-MB 453 and T47D cell lines. **b**, Neuregulin-2 β signalling through ErbB3 and ErbB4 receptors. rNRG-2 β was tested on cell lines transfected with defined ErbB-family receptors. Only cells with ErbB3 and/or ErbB4 receptors were activated. E1, EGF receptor; E2, ErbB2; E3, ErbB3; E4, ErbB4. Immunoprecipitating antibodies (IPAb): a1, anti-EGF receptor; a2, anti-ErbB2; a3, anti-ErbB3; a4, anti-ErbB4. B, betacellulin; Hrg', heregulin- β 1 EGF-like domain; rN2, rNRG-2 β (EGF-like domain of neuregulin-2 β); CM, neuregulin-2 β -conditioned medium; -, negative control.

neuregulin-2 during embryogenesis by whole-mount *in situ* hybridization with the same probes. We did not detect any signal in E9.5–E10 mouse embryos (data not shown), indicating that none or very little neuregulin-2 is expressed in embryos at those developmental stages. Therefore neuregulin-2 is unlikely to be the 'missing ligand' for ErbB4 receptors¹⁵.

The structural similarity between neuregulin-2 and neuregulins suggests that the neuregulin-2 proteins may also function as ligands for ErbB family receptors. To test this, we expressed a large portion of neuregulin-2 β (including all of the extracellular domain and part of cytoplasmic domain) in CHO cells. As the sequences around the putative proteolysis sites are highly conserved between neuregulin-2 and neuregulins, a soluble form of neuregulin-2 β protein should be released from its precursors to the culture medium, as in the case of neuregulins^{1–4}. We treated cells expressing ErbB family receptors (MDA-MB453 and T47D breast cancer cell lines)^{22,23} with conditioned medium from stably transfected CHO cells. As shown in Fig. 4a, ErbB2, ErbB3 and ErbB4 receptors were activated by neuregulin-2 β -conditioned medium. But as ErbB family receptors can form ligand-induced heterodimers, the activation of ErbB2/3/4 receptors could be due to direct or indirect interaction with neuregulin-2 β . We also expressed the EGF-like domain (amino acids 240–305; Fig. 1) of neuregulin-2 β in bacteria and produced a refolded neuregulin-2 β protein fragment (rNRG-2 β) from inclusion bodies. rNRG-2 β can activate ErbB-family receptors in our breast-tumour cell lines (data not shown), suggesting that like neuregulins, the EGF-like domain is the functional domain for activating ErbB-family receptors.

To determine which of the ErbB family receptors is involved in neuregulin-2 β signalling, we tested rNRG-2 β on cell lines expressing defined combinations of ErbB receptors. We did not detect rNRG-2 β activation of EGF receptors in the Ba/F3 (EGFR) cell line or of ErbB2 receptor in the Fischer rat 3T3 cell line (Fig. 4b), whereas our positive control, betacellulin²⁴, stimulated these receptors. On the other hand, rNRG-2 β stimulated ErbB4 receptor in the Ba/F3 (ErbB4) cell line, as well as ErbB2 and ErbB3 receptors in the Ba/F3 (ErbB2 + ErbB3) cell line. These results indicate that neuregulin-2 β signalling results from direct interaction with ErbB3 and/or ErbB4 receptors.

We have shown that the neuregulin-2 gene, which has structural similarity to the neuregulin gene, encodes new ligands for the ErbB3 and ErbB4 receptors. The distinct expression pattern of neuregulin-2 suggests that these proteins have specific biological functions. It will be necessary to compare neuregulin-2 with neuregulins and other ligands for ErbB-family receptors, including the temporal and spatial regulation of their expression, in order to understand the function of this multiligand/multireceptor signalling network.

Methods

Cloning of neuregulin-2 cDNAs. Two pools of degenerate oligonucleotides were synthesized based on two conserved regions of the neuregulin sequences, one in the immunoglobulin-like domain and the other in the EGF-like domain. Phages from an adult rat cerebellum cDNA library (gift from D. Zhao) were used as templates for PCR. Two steps were used to reduce neuregulin sequences and select neuregulin-related sequences. First, PCR products were digested with *Bcl*I and separated by agarose gel electrophoresis, because there is a *Bcl*I site in rat neuregulin cDNA⁴. DNA fragments of expected sizes were isolated from the agarose gel and reamplified with the same primers. Final PCR products were subcloned into pBlueScriptII vector (Stratagene). Second, individual clones were hybridized with a neuregulin probe under low-stringency conditions and positive clones were sequenced. We identified one clone, n9, which has significant homology to neuregulins. ³²P-labelled probes from the n9 insert were used to screen the cDNA library (~500,000 clones) and several positive clones were identified. The insert of each clone was sequenced in both directions and analysed.

Northern blot and *in situ* hybridization. Poly(A)⁺ RNA was purified from tissues by using a FastTrack kit (Invitrogen). RNA samples were separated on

agarose gels and transferred to nylon filters by standard procedures. Filters were hybridized with ³²P-labelled probes under high-stringency conditions. A probe was generated by random priming of a fragment of neuregulin-2 cDNAs spanning the EGF-like plus the Ig-like domains. The highly conserved transmembrane domain and adjacent sequence were excluded. The probe would hybridize to both neuregulin-2 α and neuregulin-2 β transcripts. *In situ* hybridization was done essentially as described²⁵. We used a digoxigenin-labelled cRNA probe spanning the EGF-like plus the Ig-like domains. Several other probes derived from different parts of neuregulin-2 cDNAs (that is, the EGF-like domain only, the Ig domain only) also gave essentially the same hybridization pattern.

Expression of recombinant neuregulin-2 proteins. The insert of a partial neuregulin-2 β cDNA clone was subcloned into the pRc/CMV expression vector (Invitrogen) and stably transfected into CHO cells. Serum-free conditioned medium was collected. Negative control media were conditioned medium from CHO cells or from CHO cells transfected with an unrelated gene. For expression of rNRG-2 β in *E. coli*, the EGF-like domain of neuregulin-2 β (residues 240–305) was subcloned into pQE32 expression vector with an N terminus 6 $\times$ histidine tag (Qiagen). Protocols for solubilization and refolding of proteins from inclusion bodies were essentially as described²⁴, except that refolded proteins were not purified further. The final rNRG-2 β protein concentration is ~500 μ g ml⁻¹.

Tyrosine-phosphorylation assay. MDA-MB 453 and T47D cells were starved in serum-free medium for 2–6 h before addition of neuregulin-2 β conditioned medium, negative control medium, or heregulin- β 1 (extracellular portion, 20 ng ml⁻¹; from S. J. Burden). After 5–10 min at room temperature, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1 SDS, 1 mM sodium orthovanadate, 50 μ g ml⁻¹ aprotinin, 0.5 mM PMSF), immunoprecipitated with rabbit antibodies (Santa Cruz Biotechnology) specific for ErbB2 (C18), ErbB3 (C17) or ErbB4 (C18). Immunoprecipitated proteins were collected on protein A-Sepharose beads, analysed by western blotting with an anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology). Antibody binding was detected by enhanced chemiluminescence (Amersham Life Science). The recombinant Ba/F3 cell lines expressing ErbB family receptors have been described, as have protocols for stimulating and analysing ErbB-family receptor tyrosine-phosphorylation^{24,26,27}. EGFR and ErbB2 expression in Fischer rat 3T3 (F3T3) was described²⁸. Human recombinant betacellulin (R&D Systems) was used at 200 ng ml⁻¹. Chemically synthesized heregulin- β 1 65-mer²⁹ was used at 94 ng ml⁻¹. Although we can detect the activity of rNRG-2 β at a dilution of 1:50,000, it was routinely used at a dilution of 1:100 to ensure saturated receptor phosphorylation.

Received 23 April 1996; accepted 26 February 1997.

1. Falls, D. L., Rosen, K. M., Corfas, G., Lane, W. S. & Fischbach, G. D. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. *Cell* 72, 801–815 (1993).
2. Marchionni, M. A. *et al.* Glial growth factors are alternatively spliced ErbB2 ligands expressed in the nervous system. *Nature* 362, 312–318 (1993).
3. Holmes, W. E. *et al.* Identification of heregulin, a specific activator of p185erbB2. *Science* 256, 1205–1210 (1992).
4. Wen, D. *et al.* Neu differentiation factor; a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. *Cell* 69, 559–572 (1992).
5. Marchionni, M. A. Neu tack on neuregulin. *Nature* 378, 334–335 (1995).
6. Lemke, G. Recitative and ARIA. *Nature* 362, 291–292 (1993).
7. Carraway, K. L. & Burden, S. J. Neuregulins and their receptors. *Curr. Opin. Neurobiol.* 5, 606–612 (1995).
8. Plowman, G. D. *et al.* Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. *Proc. Natl Acad. Sci. USA* 90, 1746–1750 (1993).
9. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C. & Aaronson, S. A. Isolation and characterization of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. *Proc. Natl Acad. Sci. USA* 86, 9193–9197 (1989).
10. Schechter, A. L. *et al.* The neu oncogene: an erbB-related gene encoding a 185,000-M_r tumour antigen. *Nature* 312, 513–516 (1984).
11. Hynes, N. E. & Stern, D. F. The biology of erbB/neu/Her-2 and its role in cancer. *Biochim. Biophys. Acta* 1198, 165–184 (1994).
12. Sliwkowski, M. X. *et al.* Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. *J. Biol. Chem.* 269, 14661–14665 (1994).
13. Plowman, G. D. *et al.* Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. *Nature* 366, 473–475 (1993).
14. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. *Nature* 378, 386–390 (1995).
15. Gassmann, M. *et al.* Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. *Nature* 378, 390–394 (1995).
16. Lee, K. F. *et al.* Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature* 378, 394–398 (1995).
17. Chang, H. & Gilbert, W. Cloning and characterization of a new factor related to ARIA/NDF/GGE. *Soc. Neurosci. Abstr.* 20, 1694 (1994).

18. Williams, A. F. & Barclay, A. N. The immunoglobulin superfamily—domains for cell surface recognition. *Annu. Rev. Immunol.* 6, 381–405 (1988).
19. Carpenter, G. & Cohen, S. Epidermal growth factor. *J. Biol. Chem.* 265, 7709–7712 (1990).
20. Wen, D. *et al.* Structural and functional aspects of the multiplicity of Neu differentiation factors. *Mol. Cell. Biol.* 14, 1909–1919 (1994).
21. Corfas, G., Rosen, K. M., Aratake, H., Krauss, R. & Fischbach, G. D. Differential expression of ARIA isoforms in the rat brain. *Neuron* 14, 103–115 (1995).
22. Wallasch, C. *et al.* Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. *EMBO J.* 14, 4267–4275 (1995).
23. Beerli, R. R. *et al.* Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. *Mol. Cell. Biol.* 15, 6496–6505 (1995).
24. Riese, D. J. *et al.* Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. *Oncogene* 12, 345–353 (1996).
25. Schaeren-Wiemers, N. & Gerfin-Moser, A. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: *in situ* hybridization using digoxigenin-labelled cRNA probes. *Histochemistry* 100, 431–440 (1993).
26. Riese, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C. & Stern, D. F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. *Mol. Cell. Biol.* 15, 5770–5776 (1995).
27. DiGiovanna, M. P. & Stern, D. F. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. *Cancer Res.* 55, 1946–1955 (1995).
28. Dobashi, Y. & Stern, D. F. Membrane-anchored forms of EGF stimulate focus formation and intercellular communication. *Oncogene* 6, 1151–1159 (1991).
29. Barbacci, E. G. *et al.* The structural basis for the specificity of epidermal growth factor and heregulin binding. *J. Biol. Chem.* 270, 9585–9589 (1995).

Supplementary information is available on Nature's World-Wide Web site (<http://www.nature.com>) or as paper copy from Mary Sheehan at the London editorial office of Nature.

Acknowledgements. We thank D. Zhao for the rat cerebellum cDNA library; S. J. Burden for recombinant heregulin-β1; M. P. Scott and L. Goodrich for assistance with *in situ* hybridization; M. A. Marchionni help in preparing the manuscript; and B. Guarino, G. C. Andrews and J. D. Moyer of Pfizer Central Research for synthetic heregulin-β. This work was supported in part by grants from National Cancer Institute and US Army Medical Research and Materiel Command (to D.J.R. and D.F.S.), and from the NIH (to H.C. and U.J.M.).

Correspondence and requests for materials should be addressed to H.C. (e-mail: hanchang@leland.stanford.edu).

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases

Kermit L. Carraway III*, Janet L. Weber†, Michelle J. Unger*, Jessica Ledesma†, Naichen Yu†, Martin Gassmann‡§ & Cary Lai†

* Department of Cell Biology, Harvard Medical School, and Division of Signal Transduction, Beth Israel Hospital, Boston, Massachusetts 02215, USA

† Department of Neuropathology, The Scripps Research Institute, La Jolla, California 92037, USA

‡ Molecular Neurobiology Laboratory, The Salk Institute, La Jolla, California 92037, USA

The neuregulins (NRGs) are a family of multipotent epidermal-growth-factor-like (EGF-like) factors that arise from splice variants of a single gene. They influence the growth, differentiation, survival and fate of several cell types. We have now discovered a set of new neuregulin-like growth factors, which we call neuregulin-2 (NRG-2): these are encoded by their own gene and exhibit a distinct expression pattern in adult brain and developing heart. Like NRG-1, the EGF-like domain of the new ligands binds to both the ErbB3- and ErbB4-receptor tyrosine kinases. However, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles from NRG-1. Our results indicate that NRG-1 and NRG-2 mediate distinct biological processes by acting at different sites in tissues and eliciting different biochemical responses in cells.

The neuregulins (NRG-1) are a family of polypeptide growth factors that are thought to be critical for the developing heart and nervous system, and in the generation and progression of tumours.

In the peripheral nervous system, neuronally derived NRG-1 acts at the neuromuscular junction to promote the end-stage differentiation of muscle cells^{1–4}, and in developing nerves to promote the proliferation, survival and differentiation of Schwann cells^{4–6}. NRG-1 is also essential in the developing heart: neuregulin-deficient mice fail to form ventricular trabeculae and die in mid-gestation^{7–10}. NRG-1 may also play a role in oncogenesis as it can indirectly activate the ErbB2-receptor protein-tyrosine kinase (PTK) whose overexpression correlates with a poor prognosis of some cancer patients¹¹. The molecular cloning of these bioactivities has revealed that NRG-1, separately identified as glial growth factors (GGFs), acetylcholine-receptor-inducing activity (ARIA), heregulins (HRGs), and neu differentiation factor (NDF), are the alternatively spliced products of a single gene^{12–15}. NRG-1 binds to ErbB3 and ErbB4 (refs 16–19), two members of the ErbB subfamily of receptor PTKs, and stimulates the tyrosine phosphorylation of other ErbB receptors through receptor heterodimerization^{19–22}.

We have identified a new NRG-1-like gene called neuregulin (NRG-2). Three distinct complementary DNAs were obtained by screening an adult mouse brain cDNA library with a NRG-1 probe; a composite amino-acid sequence is presented in Fig. 1a. NRG-2 is distantly related to NRG-1 (~35% identity) but exhibits a similar overall domain structure. It includes a single EGF-related motif with the same spacing between the third and fourth cysteine residues as that for EGF (and related molecules that bind to the EGF receptor) but distinct from NRG-1 (see Supplementary Information). NRG-2 carries a single immunoglobulin (Ig)-like domain that is ~36% identical to similar domains found in a subset of NRG-1 splice variants. The transmembrane segment is highly conserved (Fig. 1a, b) and, by analogy with NRG-1, cleavage of the NRG-2 precursor may yield a soluble NRG-2 isoform. The structure of the NRG-2 cDNAs indicates that alternative splicing similar to those found in NRG-1 (refs 12, 14) also generates multiple NRG-2 EGF-like isoforms, including a β1-like (clone 16A) and an α-like form (clone 5). The splicing alters the carboxy-terminal portion of the EGF-like motif; the NRG-2 and NRG-1 β1-like forms are particularly highly conserved in this region, with 16/28 identical residues.

To identify sites of NRG-2 expression we analysed, by northern blotting, messenger RNA samples from a series of adult rat tissues (Fig. 2a). Neural expression of NRG-2 mRNA was observed primarily in the cerebellum and olfactory bulb; a transcript was also detected in liver. By whole-mount *in situ* hybridization in mouse E9.5 embryos, NRG-2 mRNA was detected in the endothelial lining of the heart, with the highest mRNA levels being found in the atrium and lower levels in the ventricle and outflow tract (Fig. 2b, c). This profile is complementary to that of NRG-1, which is expressed at high levels in the ventricular endothelium and only weakly in the atrial endothelium⁷. It also differed from NRG-1 in the developing hindbrain, where NRG-1 has been identified in rhombomeres 2, 4 and 6 (ref. 7) and NRG-2 was not detected. In the adult rat, expression of NRG-2 and NRG-1 mRNA was compared by *in situ* hybridization. In the cerebellum, NRG-2 mRNA was detected in granule and Purkinje cells (Fig. 2k), whereas NRG-1 was found mainly in Golgi II cells^{23,24} (Fig. 2j). Cerebellar granule cells also express ErbB4 mRNA (C.L., unpublished results), suggesting a possible autocrine role for NRG-2. In the hindbrain, the NRG-2 mRNA was weakly detectable in the motor trigeminal nucleus (Fig. 2i), compared to a strong NRG-1 signal (Fig. 2h). In the hippocampus, granule cells of the dentate gyrus express NRG-2 (Fig. 2g), where no NRG-1 was detected (Fig. 2f). The cholinergic cells in the basal forebrain that express NRG-1 mRNA^{23,24} (Fig. 2d) are only faintly positive for NRG-2 (Fig. 2e). NRG-2 mRNA was not detected in the hypothalamus^{23,24}, which produces the pituitary-derived NRG-1 known as GGF (not shown). These profiles indicate that in the adult brain NRG-1 and NRG-2 are expressed in largely non-overlapping neural cell populations, suggesting that the two ligands have distinct functional roles.

§ Present address: Division of Neurobiology, National Institute for Medical Research, Mill Hill, London NW7 1AA, UK.

Activation of ErbB4 by the Bifunctional EGF Family Hormone Epiregulin is Regulated by ErbB2

David J. Riese II¹, Toshi Komurasaki⁴, Gregory D. Plowman², and David F. Stern³

Departments of ^{1,3}Pathology and ³Biology
Yale University
New Haven, Connecticut 06520-8023

²Bristol-Myers-Squibb Pharmaceutical Research Institute
Seattle, Washington 98121
and
Sugen, Inc.
Redwood City, California 94063-4720

⁴Molecular Biology Laboratory
Taisho Pharmaceutical Research Center
Ohmiya-shi, Saitama 330, JAPAN

Running Title: Epiregulin Activates ErbB4

Keywords: Epiregulin, Betacellulin, ErbB4, Neu, ErbB2, EGF Receptor

¹Current Address:

Department of Medicinal Chemistry and Molecular Pharmacology
Purdue University School of Pharmacy and Pharmacal Sciences
West Lafayette, IN 47907

³To whom correspondence should be addressed:

Department of Pathology, BML-342
Yale University School of Medicine
P.O. Box 208023
New Haven, CT 06520-8023
Tel: (203) 785-4832 FAX: (203) 785-7467
Email: Stern@Biomed.med.yale.edu

Summary

Epiregulin (EPR) is a recently-described member of the epidermal growth factor (EGF) family of peptide growth factors. The ever-expanding size of the EGF family has made distinguishing the activities of these hormones paramount. We show here that EPR activates two members of the ErbB family of receptor tyrosine kinases, epidermal growth factor receptor (EGFR) and ErbB4. Therefore by these criteria, EPR is qualitatively similar to another EGF family hormone, betacellulin (BTC). Yet, here we also demonstrate quantitative differences between EPR and BTC. EPR stimulates higher levels of EGFR phosphorylation than does BTC, while BTC stimulates higher levels of ErbB4 phosphorylation than does EPR. Moreover, the EPR and BTC dose response curves show that while EGFR is more sensitive to EPR than is ErbB4, ErbB4 is more sensitive to BTC than is EGFR. Finally, ErbB2, which is not activated by EPR when expressed on its own, increases the sensitivity of ErbB4 for activation by EPR. Therefore, these results establish that EPR exhibits novel activities and modes of regulation, which may have significant implications for EPR function *in vivo*.

Introduction

The continuing discovery of novel members of the epidermal growth factor (EGF) family of peptide growth factors has led to an increased appreciation of the functional differences among these hormones, as well as a realization of the complex hormone-receptor interactions fostered by these peptides. EGF, transforming growth factor alpha (TGF α), and amphiregulin (AR) all bind exclusively to the EGF receptor (EGFR). Yet, these hormones can also activate in *trans* (transmodulate) the other three ErbB family receptors (Neu/ErbB2/Her2, ErbB3/Her3, ErbB4/Her4) through ligand-induced receptor heterodimerization with the EGFR [1-8]. Other EGF family hormones bind multiple receptors. Neuregulin (NRG) and Neuregulin2 (NRG2) bind ErbB3 and ErbB4 and transmodulate EGFR and ErbB2 [9-16]. Betacellulin (BTC) combines some of the properties of EGF and NRG by activating EGFR and ErbB4 [7].

EPR was initially purified from the conditioned medium of a tumorigenic clone of NIH3T3 fibroblasts. It competes with EGF for binding to A431 cells, which overexpress EGFR, suggesting that EPR is a ligand for EGFR [17]. Since at least one of the EGF family hormones that activates EGFR also activates ErbB4, we wished to evaluate EPR function in a set of cell lines expressing all four ErbB family receptors, both singly and in every pairwise combination.

We demonstrate here that EPR activates not only EGFR, but ErbB4 as well. However, the dose-response curves for BTC and EPR in a cell line expressing both EGFR and ErbB4 are markedly different. While ErbB4 is more responsive to BTC than is EGFR, ErbB4 is less responsive to EPR than is EGFR. Moreover, ErbB2 expression increases saturated ErbB4 phosphorylation in response to EPR and dramatically enhances the sensitivity of ErbB4 for activation by EPR as well. In this respect EPR resembles NRG, which displays a low affinity for ErbB3 that increases in cells where ErbB2 is co-expressed [12].

Experimental Procedures

Cell Lines and Cell Culture

BaF3 is an immortal mouse lymphoblastoid cell line [31]. BaF3-derived cell lines expressing combinations of ErbB family receptors have been described previously [14]. CEM is an immortal human T-lymphoblastoid cell line which does not endogenously express EGF receptor, ErbB2, ErbB3, or ErbB4. CEM-derived cell lines expressing ErbB4 or ErbB2 and ErbB4 have been described previously [10]. Cell culture conditions were as described [10,14].

Growth Factors

Recombinant human EPR was produced in *Bacillus brevis* [Nakazawa, *et al.*, in preparation]. Recombinant NRG β was the generous gift of Kerry Russell and Jeffrey Bender (Yale University). We are grateful to Jim Moyer, Brad Guarino, and Glenn Andrews (Pfizer Central Research, Groton, CT) for synthetic NRG β [32]. Recombinant BTC was purchased from R&D Systems (Minneapolis, MN, USA), while recombinant TGF α was purchased from Collaborative Biomedical Products (Bedford, MA).

Stimulation and Analysis of Receptor Phosphorylation

The conditions for stimulation of ErbB family receptor tyrosine phosphorylation have been described previously [7, 14]. The analysis of ErbB family receptor tyrosine phosphorylation by immunoprecipitation and anti-phosphotyrosine immunoblotting has been described previously [7,14]. Immunoprecipitating anti-receptor antibodies were anti-EGFR mouse monoclonal antibody 528 [33], anti-ErbB2 mouse monoclonal antibody TA-1 (OP-39, Calbiochem), anti-ErbB3 rabbit polyclonal antiserum SC-285 (Santa Cruz Biotechnology), and anti-

ErbB4 rabbit polyclonal antiserum SC-283 (Santa Cruz Biotechnology). Specificity of anti-receptor antibodies has been verified by testing for cross-reactivity (data not shown).

Immunoblot autoradiographs were digitized using a Hewlett-Packard 3p flat-bed scanner set for 600dpi resolution and controlled by Hewlett-Packard Deskscan II for Macintosh software. Images were cropped using Adobe Photoshop and band intensity was quantified using NIH Image software. Net receptor activation was calculated by subtracting the amount of tyrosine phosphorylation observed in samples from mock-stimulated cells.

Results

EPR activates EGFR

We first sought to identify which ErbB family receptors are activated by EPR when the receptors are expressed individually. We previously developed a panel of cell lines based on the mouse BaF3 hematopoietic cell line that expresses the four ErbB family receptors, both singly and in every pairwise combination. Hence, we incubated with EPR the BaF3 cell lines ectopically expressing EGFR, ErbB2, or ErbB4. EPR, like BTC, stimulated EGFR tyrosine phosphorylation, consistent with published results suggesting that EPR binds EGFR [17] (Fig. 1, "EGFR" panel; compare lanes "E" and "B" with "M"). However, EPR did not stimulate phosphorylation of ErbB2 or ErbB4 (Fig 1, "ErbB2" and "ErbB4" panels; compare lanes "E" and "M"). In contrast, the positive control NRG β stimulated ErbB2 tyrosine phosphorylation and both NRG β and BTC stimulated ErbB4 phosphorylation. The ErbB2 phosphorylation observed in BaF3/ErbB2 cells stimulated with NRG is the result of transmodulation of ErbB2 by the NRG receptor ErbB3, which is endogenously expressed at low levels in BaF3 cells [14]. Neither EPR nor any of the other EGF family ligands tested to date stimulated ErbB3 tyrosine phosphorylation in BaF3 cells expressing only ErbB3 (data not shown) [7,8,14]. However, since ErbB3 lacks tyrosine kinase activity [18], these experiments do not rule out EPR binding to ErbB3.

Since EPR activates EGFR, we next determined whether EPR activates the other three ErbB family receptors *in trans* via EGFR. A panel of BaF3 cell lines ectopically expressing EGFR together with one of the other three ErbB family receptors was stimulated with EPR. EPR activated the EGFR in all three cell lines (Fig. 2a; compare "E" " α 1" lanes with the "M" " α 1" lanes). Both EPR ("E" lanes) and the positive control TGF α ("T" lanes) strongly activated ErbB2 in the cell line coexpressing EGFR+ErbB2 (Fig. 2a, "EGFR+ErbB2" panel; " α 2" lanes). In contrast,

neither EPR nor TGF α activated ErbB3 or ErbB4 (Fig. 2a, "EGFR+ErbB3" and "EGFR+ErbB4" panels; " α 3" or " α 4" lanes). This is consistent with the conclusion that ErbB2 is a preferential target for transmodulation by the EGFR compared to the other ErbB family receptors [7,8,19-21]. However, higher concentrations of EPR than those used for these experiments did stimulate ErbB4 phosphorylation in the EGFR+ErbB4 cell line (see below, Fig. 5a).

Since ErbB3 lacks functional kinase activity, EGF family hormones can activate ErbB3 only in the presence of another ErbB family receptor, particularly ErbB2, which permits the highest levels of ErbB3 phosphorylation by NRG [11,12,14]. Therefore, BaF3 cells expressing both ErbB2 and ErbB3 or both ErbB3 and ErbB4 were stimulated with EPR to determine if ErbB3 is a receptor for EPR. In the ErbB2+ErbB3 cell line, the positive control NRG β activated both receptors (Fig 2b, "ErbB2+ErbB3" panel, compare "N" lanes with "M" lanes), while in the ErbB3+ErbB4 cell line NRG β stimulated a marked increase in ErbB3 phosphorylation and modest increase in ErbB4 phosphorylation (Fig 2b, "ErbB3+ErbB4" panel, compare "N" lanes with "M" lanes). In contrast, EPR did not stimulate receptor phosphorylation in either of these cell lines, suggesting that ErbB3 is not a receptor for EPR (Fig. 2b; compare "E" lanes with "M" lanes).

EPR activates ErbB4 in CEM cells

BTC activates both ErbB4 and EGFR when expressed individually [7]. We tested whether EPR behaves like BTC and also activates ErbB4 expressed alone using derivatives of the CEM human T-lymphoblastoid cell line that ectopically expresses ErbB4 alone or both ErbB2 and ErbB4 [10]. EPR activated ErbB4 in CEM cells expressing ErbB4 alone and both receptors in CEM cells expressing ErbB2 and ErbB4 together (Fig. 3; compare "E" lanes to "M" lanes). In experiments done in parallel using identical growth factor concentrations, EPR did not activate ErbB4 in BaF3

cells expressing ErbB4 alone (also see Fig. 1) but stimulated ErbB2 and ErbB4 phosphorylation in BaF3 cells expressing both ErbB2 and ErbB4 (data not shown). It is unclear why EPR failed to activate ErbB4 in the BaF3 cells expressing ErbB4 alone. Nonetheless, because EPR activates EGFR as well as ErbB4, EPR resembles BTC, which also activates these receptors [7].

EPR stimulates EGFR more than ErbB4 and EGFR is more sensitive than ErbB4 to EPR

Since EPR can activate EGFR and ErbB4 when the receptors are expressed individually, we compared EGFR and ErbB4 phosphorylation in BaF3/EGFR and CEM/ErbB4 cells stimulated with increasing concentrations of EPR (Fig 4a). At saturation, EPR stimulated a slightly higher level of EGFR phosphorylation (1.7 fold) than did BTC, while EPR stimulated a much lower level of ErbB4 phosphorylation (0.3 fold) than did BTC (Fig. 4c). We next compared the dose sensitivity of EGFR and ErbB4 to EPR stimulation by plotting receptor phosphorylation relative to the maximal amounts of receptor phosphorylation stimulated by EPR (Fig. 4d) to identify the EPR concentrations required for half-maximal receptor phosphorylation (Table 1). Half-maximal EGFR phosphorylation occurred at an EPR concentration of approximately 380ng/ml (Fig. 4d; Table 1). In contrast, half-maximal ErbB4 phosphorylation required about a 4-fold higher concentration of EPR, with half-maximal activation occurring at an EPR concentration of approximately 1790ng/ml (Fig. 4d; Table 1).

ErbB2 expression increases ErbB4 activation by EPR and sensitivity to EPR

The affinity of NRG for cells expressing ErbB3 is greater when these cells also express ErbB2 [12]. Hence, we evaluated the possibility that ErbB2 modulates ErbB4 activation by EPR by stimulating CEM/ErbB4 and CEM/ErbB2+ErbB4 cells with

increasing concentrations of EPR (Fig. 4a-b). Relative to the BTC positive control, EPR stimulated 2-fold higher levels of ErbB4 phosphorylation in the ErbB2+ErbB4 cell line than in cells expressing ErbB4 alone (Fig. 4c). Therefore, ErbB2, which is not activated by EPR when expressed by itself (Fig. 1), doubles the magnitude of ErbB4 activation by EPR at saturation. We next examined the effects of ErbB2 expression on the sensitivity of ErbB4 to EPR (Fig. 4d). Half-maximal ErbB4 phosphorylation occurred at an EPR concentration of approximately 1790ng/ml in the cell line expressing ErbB4 alone (Fig. 4d; Table 1), but occurred at an EPR concentration of approximately 630ng/ml (Fig. 4d; Table 1) in the ErbB2+ErbB4 cell line. This shift in the EPR dose-response curve in the ErbB2+ErbB4 cell line compared to the ErbB4 cell line suggests that ErbB2 expression increases the affinity of ErbB4 for EPR and implies that ErbB2-ErbB4 heterodimers have a higher affinity for EPR than do ErbB4-ErbB4 homodimers.

The EPR and BTC dose response curves are different in cells expressing EGFR and ErbB4

EPR resembles BTC in its ability to activate either EGFR or ErbB4 when expressed individually [7]. Yet, at saturation EPR stimulated almost 2-fold more EGFR phosphorylation than BTC, while BTC activated about 3-fold more ErbB4 phosphorylation than did EPR (Fig. 4a, 4c). This suggested that BTC and EPR are functionally distinct. Hence, we compared EGFR and ErbB4 phosphorylation following stimulation with increasing concentrations of BTC or EPR in a BaF3 cell line that expresses both EGFR and ErbB4 (Fig 5a).

We first compared the magnitude of receptor phosphorylation stimulated by EPR and BTC by plotting receptor phosphorylation relative to the maximal phosphorylation stimulated by BTC (Fig. 5b-c). In agreement with results presented above (Fig. 4a, 4c), EPR stimulated higher saturated levels of EGFR phosphorylation

than BTC, while BTC activated greater ErbB4 phosphorylation than did EPR (Fig. 5a, 5c). However, the magnitude of these differences was much less in the EGFR+ErbB4 cell line compared to the differences in phosphorylation we observed between the cell lines expressing EGFR and ErbB4 individually (Fig. 4a, 4c).

Next, we compared the sensitivities of EGFR and ErbB4 to BTC and EPR by identifying the growth factor concentrations required for half-maximal receptor phosphorylation. Half-maximal EGFR activation occurred at a BTC concentration of approximately 35ng/ml, while half-maximal ErbB4 activation occurred at a BTC concentration of approximately 5ng/ml (Fig. 5b; Table 1). In contrast, half-maximal EGFR activation occurred at an EPR concentration of approximately 320ng/ml, while half-maximal ErbB4 activation occurred at an EPR concentration of approximately 790ng/ml (Fig. 5c; Table 1). This suggests that ErbB4 is 7-fold more sensitive to BTC than is EGFR, while EGFR is more than two-fold more sensitive to EPR than is ErbB4.

Finally, these results illustrate that EGFR expression, like ErbB2 expression, shifts the EPR dose-response curve in cells expressing ErbB4. Half-maximal ErbB4 phosphorylation in a CEM cell line expressing ErbB4 alone occurs at an EPR concentration of 1790ng/ml (Fig. 4d; Table 1). In contrast, half-maximal ErbB4 phosphorylation in BaF3 cells expressing both EGFR and ErbB4 occurs at 790ng/ml (Fig. 5c; Table 1).

EPR activates ErbB family receptor coupling to IL3-independence

While EPR and BTC stimulate qualitatively identical patterns of receptor phosphorylation, these hormones are quantitatively distinct. One possible mechanism is that EPR and BTC stimulate EGFR and ErbB4 tyrosine phosphorylation at different sites. This would account for the higher levels of EGFR activation by EPR compared to BTC and the higher levels of ErbB4 activation by BTC

compared to EPR. Moreover, this would also enable these hormones to couple to distinct receptor effectors and physiologic responses. Therefore, we compared EPR and BTC induction of receptor coupling to physiologic responses. BaF3 cells require interleukin-3 (IL3) for survival and for proliferation. However, activation of either EGFR or ErbB2 permits survival of BaF3 cells in the absence of IL3 [7,14]. EPR, like BTC [7], induces IL3-independent survival in BaF3 cells expressing EGFR, but not in vector control BaF3 cells or cells expressing ErbB2 (Fig. 6). (The IL3-independent response of BaF3 cells expressing ErbB2 to NRG is the result of ErbB2 transmodulation by endogenous ErbB3 in these cells [14].) Both EPR and BTC induced IL3 independence in cells co-expressing ErbB2 and ErbB4, presumably through ErbB2 transmodulation by ErbB4 (Fig. 6). Nonetheless, the response to BTC and NRG is greater than the response to EPR, which may reflect subtle functional differences between BTC and EPR.

Discussion

We previously demonstrated that the EGF family of peptide growth factors can be divided into three distinct functional groups [8] (Figure 7). The first group consists of EGF, TGF α , and AR. These hormones bind and activate only the EGFR, but they can activate the other three ErbB family receptors *in trans* via heterodimerization with the EGFR. The second group consists of NRG and NRG2, which bind ErbB3 and ErbB4 and transmodulate EGFR and Neu via the binding receptors. The third group consists of BTC, which binds and activates both EGFR and ErbB4. Recent data suggests that HB-EGF may also bind and activate EGFR and ErbB4, which would make HB-EGF a member of this group as well [22].

While EPR activates both EGFR and ErbB4, the interactions of EPR with these two receptors appear to be quite different. Compared to BTC, EPR stimulates higher levels of EGFR phosphorylation and lower levels of ErbB4 phosphorylation. While both EPR and BTC stimulate EGFR and ErbB4 homodimerization and signaling, the geometry of the receptor dimers induced by EPR and BTC may be subtly different; the alignment of the kinase domain of one receptor molecule of a receptor homodimer with the autophosphorylation site of the other receptor molecule following EPR stimulation could be different from this alignment following BTC stimulation, affecting the cross-phosphorylation within receptor dimers. Alternatively, ligand-induced changes in the conformation of the receptor kinase domains might be different when the receptors are activated by BTC and EPR. Therefore, BTC and EPR may differentially stimulate receptor kinase activity. In either scenario, BTC and EPR could stimulate receptor autophosphorylation on different tyrosine residues, which could also be reflected in differences in gross levels of receptor phosphorylation. In this manner BTC and EPR could differentially modulate receptor coupling to signaling effectors and physiologic responses.

Another difference between EPR and BTC is that while EGFR is much more sensitive than ErbB4 to EPR, EGFR is less sensitive than ErbB4 to BTC. This suggests that while the affinity of EPR for EGFR is higher than the affinity for ErbB4, the affinity of BTC for EGFR is lower than the affinity for ErbB4. This too suggests that BTC and EPR have distinct biological functions, even in cells with identical patterns of ErbB family receptor expression.

Another important aspect of EPR function is the observation that the sensitivity of ErbB4 for EPR and the magnitude of ErbB4 activation by EPR can be modulated by the expression of other ErbB family receptors. EGFR expression increases the sensitivity of ErbB4 for EPR, suggesting that EGFR-ErbB4 heterodimers have a higher affinity for EPR than ErbB4-ErbB4 homodimers (Figs. 4a,d; Figs. 5a,c; Table 1). Of course an alternative explanation is that the increased ErbB4 sensitivity in the presence of EGFR is due solely to EPR-induced transphosphorylation of ErbB4 by EGFR.

ErbB2 also increases the sensitivity of ErbB4 for EPR (Figs. 4a-d; Table 1). Because EPR does not activate ErbB2 in cells devoid of EGFR or ErbB4 (Fig. 1; Fig 6), the mechanism for the increased sensitivity of ErbB4 for EPR may be that ErbB2-ErbB4 heterodimers have a higher affinity for EPR than do ErbB4-ErbB4 homodimers. These results resemble observations made with NRG, which does not bind to ErbB2, binds with low affinity to cells expressing ErbB3, and binds with higher affinity to cells that express both ErbB2 and ErbB3 [Sliwkowski, et al., 1994]. ErbB2 expression also increases the magnitude of ErbB4 activation by EPR.

These observations that ErbB4 activation by EPR can be influenced by EGFR or ErbB2 is consistent with existing models for receptor heterodimerization and transmodulation. It has been proposed that receptor heterodimerization is mediated through low-affinity hormone-receptor interactions and heterotypic receptor-receptor contacts, after which there is cross-phosphorylation by the receptor

kinase domains [23]. It is possible that EGFR and ErbB2 are favored over ErbB4 for dimerization with ErbB4 in the presence of EPR. Therefore, there would be greater ErbB4 (hetero)dimerization in cells expressing EGFR and ErbB4 or Neu and ErbB4 than in cells expressing ErbB4 alone. This may account for the increased sensitivity of ErbB4 for EPR in the presence of EGFR or ErbB2. It is also possible that ErbB2 is a better kinase for ErbB4 than ErbB4 itself. Consequently, ErbB2 may cross-phosphorylate more ErbB4 tyrosine residues in receptor heterodimers than ErbB4 would in receptor homodimers. Similarly, ErbB2 may phosphorylate the same tyrosine residues as ErbB4 to a greater extent than does ErbB4. Either of these last two possibilities would account for the increased tyrosine phosphorylation of ErbB4 by EPR in the presence of ErbB2.

As this work was being prepared for submission, another group reported that radiolabeled EPR can be cross-linked to EGFR and ErbB4 in human breast tumor cell lines but not to ErbB2 or ErbB3. Furthermore, EPR stimulated high levels of EGFR and ErbB4 tyrosine phosphorylation, and more modest levels of ErbB2 and ErbB3 tyrosine phosphorylation [24]. Because the cell lines used in these studies express at least two and in some cases all four ErbB family receptors, some caution must be used in interpreting these results. Nonetheless, these data are entirely consistent with our findings that EGFR and ErbB4 are the receptors for EPR.

To date there have been only a few clues to EPR function. EPR transcripts are not detected in normal adult mouse liver, kidney, brain, spleen, testis, or skeletal muscles. However, low levels of EPR transcripts are detectable in adult mouse lung, smooth muscle, and heart, while more robust EPR transcription is observed in whole embryo RNA samples from 7-day-old mouse embryos [25; T. Komurasaki, unpublished data]. This implies that EPR plays a significant role in early mammalian development but only a limited role in adult tissues.

Additional hints to EPR function arise from our data suggesting that EPR is a ligand for both EGFR and ErbB4. In most contexts EGFR activation is coupled to cellular DNA synthesis and proliferation. In contrast, there is mounting evidence that activated ErbB4 is coupled to growth inhibition, differentiation, and possibly tumor suppression. NRG, a ligand for ErbB3 and ErbB4, inhibits the proliferation and stimulates the differentiation of a number of human breast tumor cell lines [26], while NRG implants stimulate the differentiation of the mouse mammary epithelium *in vivo* [27]. BTC stimulates the differentiation of pancreatic AR42J cells into insulin-secreting cells, while EGF and TGF α do not [28]. Finally, agonistic anti-ErbB4 antibodies stimulate the differentiation of human breast tumor cell lines [29], and ErbB4 overexpression in breast cancer patients correlates with progesterone receptor expression, which is a marker for longer disease-free survival and better overall prognosis [30]. Because EPR is a ligand for both EGFR and ErbB4, EPR may act as a proliferative agent in cells expressing EGFR and may act as a differentiation agent in cells that express ErbB4.

Furthermore, because EPR activation of ErbB4 is regulated by ErbB2 and activated ErbB2 appears to couple to mitogenesis and cell proliferation, the effects of EPR on cells expressing ErbB4 may be tightly linked to a balance of ErbB4 and ErbB2 expression: in cells having relatively low levels of ErbB2, EPR may have little effect, because it fails to bind to ErbB4; in cells having moderate levels of ErbB2 and high levels of ErbB4, EPR may act as a differentiation agent and inhibit cell proliferation because the relatively high levels of ErbB4 signaling may overcome the effects of ErbB2 signaling; and finally, in cells having relatively high levels of ErbB2 relative to ErbB4, EPR may stimulate such high levels of ErbB2 signaling that the effects of ErbB4 signaling are overcome and cell proliferation is stimulated. In sum, our data suggests that the physiologic response to EPR will be dictated by relative levels of

EGFR, ErbB2, and ErbB4 expression, and not just the absolute level of expression of any single ErbB family receptor.

Acknowledgments

This work was supported in part by National Cancer Institute, United States Public Health Service Grant CA-45708 and by United States Army Medical Research and Materiel Command Grant DAMD-17-94-J-4476 (to D.F.S.). D.J.R. was supported by National Cancer Institute, United States Public Health Service Postdoctoral Training Grant HD-07149 and by United States Army Medical Research and Materiel Command Postdoctoral Fellowship DAMD-17-94-J-4036. We thank Kerry Russell and Jeffrey Bender (Yale University) for recombinant NRG β , and we thank Kerry Russell, Jeffrey Bender, and Hideo Masui (Rockefeller University) for anti-EGFR monoclonal antibody 528. We are grateful to Jim Moyer, Brad Guarino, and Glenn Andrews (Pfizer Central Research, Groton, CT) for their munificent gift of synthetic NRG β .

References

1. Stern, D.F., Heffernan, P.A., and Weinberg, R.A. (1986). *Mol. Cell. Biol.* **6**, 1729-1740.
2. King, C.R., Borrello, I., Bellot, F., Comoglio, P., and Schlessinger, J. (1988). *EMBO J.* **6**, 1647-1651.
3. Stern, D.F., and Kamps, M.P. (1988). *EMBO J.* **7**, 995-1001.
4. Goldman, R., Ben-Levy, R., Peles, E., and Yarden, Y. (1990). *Biochemistry* **29**, 11024-11029.
5. Wada, T., Qian, X., and Greene, M.I. (1990). *Cell* **61**, 1339-1347.
6. Johnson, G.R., Kannan, B., Shoyab, M., and Stromberg, K. (1993). *J. Biol. Chem.* **268**, 2924-2931.
7. Riese, D.J. II, Bermingham, Y., van Raaij, T.M., Buckley, S., Plowman, G.D., and Stern, D.F. (1996a) *Oncogene* **12**, 345-353.
8. Riese, D.J. II, Kim, E.D., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, G.D., and Stern, D.F. (1996b) *J. Biol. Chem.* **271**, 20047-20052.
9. Culouscou, J.-M., Plowman, G.D., Carlton, G.W., Green, J.M., and Shoyab, M. (1993). *J. Biol. Chem.* **268**, 18407-18410.
10. Plowman, G.D., Green, J.M., Culouscou, J.-M., Carlton, G.W., Rothwell, V.M., and Buckley, S. (1993b) *Nature* **366**, 473-475.
11. Carraway, K.L. III, Sliwkowski, M.X., Akita, R., Platko, J.V., Guy, P.M., Nuijens, A., Diamonti, A.J., Vandlen, R.L., Cantley, L.C., and Cerione, R.A. (1994) *J. Biol. Chem.* **269**, 14303-14306.

12. Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., Fendly, B.M., Cerione, R.A., Vandlen, R.L., and Carraway, K.L. III. (1994) *J. Biol. Chem.* **269**, 14661-14665.
13. Tzahar, E., Levkowitz, G., Karunagaran, D., Yi, L., Peles, E., Lavi, S., Chang, D., Liu, J., Yayon, A., Wen, D., and Yarden, Y. (1994) *J. Biol. Chem.* **269**, 25226-25233.
14. Riese, D.J. II, van Raaij, T.M., Plowman, G.D, Andrews, G.C., and Stern, D.F. (1995) *Mol. Cell. Biol.* **15**, 5770-5776.
15. Chang, H., Riese, D.J. II, Gilbert, W., Stern, D.F., and McMahan, U.J. (1997). *Nature* **387**, 509-512.
16. Carraway, K.L. III, Weber, J.L., Unger, M.J., Ledesma, J., Yu, N., Gassmann, M., & Lai, C. (1997). *Nature* **387**, 512-516.
17. Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K. (1995a) *J. Biol. Chem.* **270**, 7495-7500.
18. Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L. III. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 8132-8136.
19. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996b) *EMBO J.* **15**, 2452-2467.
20. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B.J., and Yarden, Y. (1996) *Mol. Cell. Biol.* **16**, 5276-5287.
21. Graus-Porta, D., Beerli, R.R., Daly, J.M., and Hynes, N.E. (1997). *EMBO J.*, **16**, 1647-1655
22. Elenius, K., Paul, S., Allison, G., Sun, J., and Klagsbrun, M. (1997) *EMBO J.* **16**, 1268-1278.

23. Lemmon, M.A., Bu, Z., Ladbury, J.E., Zhou, M., Pinchasi, D., Lax, I., Engelman, D.M., and Schlessinger, J. (1997). *EMBO J.* **16**, 281-284.
24. Komurasaki, T., Toyoda, H., Uchida, D., and Morimoto, S. Submitted.
25. Toyoda, H., Komurasaki, T., Ikeda, Y., Yoshimoto, M., Morimoto, S. (1995b). *FEBS Lett.* **377**, 403-407.
26. Peles, E., Bacus, S.S., Koski, R.A., Lu, H.S., Wen, D., Ogden, S.G., Ben Levy, R., and Yarden, Y. *Cell* **69**, 205-216.
27. Jones, F.E., Jerry, D.J., Guarino, B.C., Andrews, G.C., and Stern, D.F. (1996). *Cell Growth Diff.* **7**, 1031-1038.
28. Mashima, H., Ohnishi, H., Wakabayashi, K., Mine, T., Miyagawa, J.-i., Hanafusa, T., Seno, M., Yamada, H., and Kojima, I. (1996). *J. Clin. Invest.* **97**, 1647-1654.
29. Chen, X., Levkowitz, G., Tzahar, E., Wen, D.D., Peles, E., Cupples, R., Suggs, S.V., Bacus, S.S., Luo, Y., Trail, G., Hu, S., Silbiger, S.M., Ben Levy, R., Koski, R.A., Lu, H.S., and Yarden, Y. (1996). *J. Biol. Chem.* **271**, 7620-7629.
30. Bacus, S.S., Chin, D., Yarden, Y., Zelnick, C.R., and Stern, D.F. (1996). *Am. J. Path.* **148**, 549-558.
31. Palacios, R., and Steinmetz, M. (1985). *Cell* **41**, 727-734.
32. Barbacci, E.G., Guarino, B.C., Stroh, J.G., Singleton, D.H., Rosnack, K.J., Moyer, J.D., and Andrews, G.C. (1995) *J. Biol. Chem.* **270**, 9585-9589.
33. Gill, G.N., Kawamoto, T., Cochet, C. Le, A., Sato, J.D., Masui, H., McLeod, C., and Mendelsohn, J. (1984). *J. Biol. Chem.* **259**, 7755-7760.

Table 1

Cell Line & Receptor	[EPR] Yielding Half-maximal Receptor Activation	[BTC] Yielding Half-maximal Receptor Activation
BaF3/EGFR	380ng/ml	NT
CEM/ErbB4	1790ng/ml	NT
BaF3/EGFR+ErbB4		
EGFR:	320ng/ml	35ng/ml
ErbB4:	790ng/ml	5ng/ml
CEM/ErbB2+ErbB4		
ErbB2:	400ng/ml	NT
ErbB4:	630ng/ml	NT

Data is taken from Figures 4a-d and 5a-c.

Figure Legends

Figure 1. EPR Stimulation of Receptor Phosphorylation in BaF3 Cells Expressing a Single ErbB Family Receptor.

BaF3/EGFR, BaF3/ErbB2, and BaF3/ErbB4 cells [14] were stimulated with 200 ng/ml EPR (E), 200 ng/ml BTC (B), 188 ng/ml synthetic NRG β (N), or were mock stimulated with phosphate-buffered saline (M) as described previously [7,14]. ErbB family receptors were immunoprecipitated from lysed cells using specific anti-receptor antibodies and separated by SDS/PAGE as previously described [7,14]. Tyrosine phosphorylated ErbB family receptors were detected and visualized by immunoblotting using the 4G10 monoclonal anti-phosphotyrosine antibody as previously described [7,14].

Figure 2a,b. EPR Stimulation of Receptor Phosphorylation in BaF3 Cells Expressing Combinations of ErbB Family Receptors.

BaF3/EGFR+ErbB2, BaF3/EGFR+ErbB3, BaF3/EGFR+ErbB4, BaF3/ErbB2+ErbB3, and BaF3/ErbB3+ErbB4 cells [14] were stimulated with 200 ng/ml EPR (E), 200 ng/ml TGF α (T), 188 ng/ml synthetic NRG β (N), or were mock stimulated with phosphate buffered saline (M) as described previously [7,8,14]. EGFR (α 1), ErbB2 (α 2), ErbB3 (α 3), or ErbB4 (α 4) was immunoprecipitated from lysed cells using specific anti-receptor antibodies and separated by SDS/PAGE as previously described [7,14]. Tyrosine phosphorylated ErbB family receptors were detected and visualized by immunoblotting using the 4G10 monoclonal anti-phosphotyrosine antibody as previously described [7,14].

Figure 3. EPR Stimulation of Receptor Phosphorylation in CEM Cells Expressing Either ErbB4 Alone or Both ErbB2 and ErbB4.

CEM/ErbB4 and CEM/ErbB2+ErbB4 cells [10] were stimulated with 100 ng/ml BTC (B), 100 ng/ml recombinant NRG β (N), 1000 ng/ml EPR (E), or were mock stimulated with phosphate-buffered saline (M) as described previously [Riese, et al., 1995]. ErbB2 (α 2), or ErbB4 (α 4) was immunoprecipitated from lysed cells using specific anti-receptor antibodies and separated by SDS/PAGE as previously described [7,14]. Tyrosine phosphorylated ErbB family receptors were detected and visualized by immunoblotting using the 4G10 monoclonal anti-phosphotyrosine antibody as previously described [7,14].

Figure 4a,-d EPR Dose Response in BaF3 Cells Expressing EGFR or in CEM Cells Expressing ErbB4 alone or both ErbB2 and ErbB4.

(4a,b) BaF3/EGFR, CEM/ErbB4, or CEM/ErbB2+ErbB4 cells were stimulated with 100 ng/ml BTC (BTC), increasing concentrations of Epregrulin as indicated, or were mock stimulated with phosphate-buffered saline (Mock) as described previously [7,14]. EGFR, ErbB2, or ErbB4 was immunoprecipitated as indicated or appropriate using specific anti-receptor antibodies and separated by SDS/PAGE as previously described [Riese, et al., 1995]. Tyrosine phosphorylated ErbB family receptors were detected and visualized by immunoblotting using the 4G10 monoclonal anti-phosphotyrosine antibody as previously described [7,14].

(4c,d) Anti-phosphotyrosine immunoblot images were scanned on a Hewlett-Packard ScanJet 3p flatbed scanner set for 600dpi optical resolution. Images were cropped using Adobe Photoshop and receptor tyrosine phosphorylation was quantified using NIH Image. Net receptor tyrosine phosphorylation was calculated by subtracting the receptor tyrosine phosphorylation exhibited by mock stimulated cells. Tyrosine phosphorylation either was expressed relative to the tyrosine phosphorylation stimulated by 100 ng/ml BTC (4c) or was expressed relative to the maximal receptor tyrosine phosphorylation stimulated by EPR (4d).

Figure 5a,-c EPR and BTC Dose Response in BaF3 Cells Expressing both EGFR and ErbB4.

(5a) BaF3/EGFR+ErbB4 cells were stimulated with increasing concentrations of Betacellulin or Epregrulin or were mock stimulated with phosphate-buffered saline (Mock) as described previously [7,14]. EGFR or ErbB4 was immunoprecipitated as indicated using specific anti-receptor antibodies and separated by SDS/PAGE as previously described [7,14]. Tyrosine phosphorylated ErbB family receptors were detected and visualized by immunoblotting using the 4G10 monoclonal anti-phosphotyrosine antibody as previously described [7,14].

(5b,c) Anti-phosphotyrosine immunoblot images were scanned on a Hewlett-Packard ScanJet 3p flatbed scanner set for 600dpi optical resolution. Images were cropped using Adobe Photoshop and receptor tyrosine phosphorylation was quantified using NIH Image. Net receptor tyrosine phosphorylation was calculated by subtracting the receptor tyrosine phosphorylation exhibited by mock stimulated cells. Tyrosine phosphorylation stimulated by BTC (5b) or EPR (5c) was expressed relative to the maximal tyrosine phosphorylation stimulated by BTC.

Figure 6. EPR Stimulation of IL3-independent Responses in BaF3 Cells Expressing Various ErbB Family Receptors.

The IL3 independent responses of BaF3/LXSN (vector control), BaF3/EGFR, BaF3/ErbB2, and BaF3/ErbB2+ErbB4 cells to EPR stimulation were assayed as described earlier [7,14]. Briefly, cells were seeded in duplicate or triplicate at an initial density of 100×10^3 cells/ml in medium lacking IL3 (IL3-Free), containing IL3 (IL3), or lacking IL3 but supplemented with 10 ng/ml EPR (Epiregulin), 10 ng/ml BTC (Betacellulin), 10ng/ml synthetic NRG β (Neuregulin) or 10 ng/ml TGF α (TGF-alpha). After seeding, samples were taken every 24 hours and the viable cell density was calculated by staining cells with trypan blue and counting them in a hemacytometer. Samples were taken until the viable cells reached a saturation density. The mean and standard error densities for three to seven trials are shown. "NT" indicates not tested.

Figure 7. Venn Diagram Illustrating the Activities of EGF Family Hormones.

The three functional groups of EGF family hormones are illustrated using a Venn diagram. The diagram is based on data presented in this work and data from references 7, 8, 14, and 22.

Figure 1




Figure 2a




Figure 2b





Figure 3

Cell Line: CEM/ErbB4
Treatment: M B N E
IP: $\alpha 4$ $\alpha 4$ $\alpha 4$ $\alpha 4$



Cell Line: CEM/ErbB2+ErbB4
Treatment: M B E
IP: $\alpha 2$ $\alpha 4$ $\alpha 2$ $\alpha 4$ $\alpha 2$ $\alpha 4$




Figure 4a




Figure 4b




Figure 4c




Figure 4d




Figure 5a




Figure 5b




Figure 5c




Figure 6





Figure 7



Specificity Within the EGF Family/ErbB Receptor Family Signaling Network

David J. Riese II* and David F. Stern¹

**Department of Pathology
Yale University
New Haven, CT USA**

Correspondence to:

David F. Stern
Department of Pathology, BML-342
Yale University School of Medicine
P.O. Box 208023
New Haven, CT 06520-8023
Tel: 203-785-4832
FAX: 203-785-7467
E-mail: Stern@Biomed.med.yale.edu

*Current address:

David J. Riese II
Department of Medicinal Chemistry and Molecular Pharmacology
Purdue University School of Pharmacy and Pharmacal Sciences
1333 Heine Pharmacy Building, Room 224
West Lafayette, IN 47907-1333

I. Summary

Recent years have witnessed tremendous growth in the epidermal growth factor (EGF) family of peptide growth factors and the ErbB family of tyrosine kinases, the receptors for these factors. Accompanying this growth has been an increased appreciation for the roles these molecules play in tumorigenesis and in regulating cell proliferation and differentiation during development.

Consequently, a significant question has been how diverse biological responses are specified by these hormones and receptors. Here we discuss several characteristics of hormone-receptor interactions and receptor coupling that contribute to specificity: (1) A single EGF family hormone can bind multiple receptors; (2) A single ErbB family receptor can bind multiple hormones; (3) There are three distinct functional groups of EGF family hormones; (4) EGF family hormones can activate receptors in *trans* and this heterodimerization diversifies biological responses; (5) ErbB3 requires a receptor partner for signaling; and (6) ErbB family receptors differentially couple to signaling pathways and biological responses.

II. Introduction

The signaling network composed of the epidermal growth factor (EGF) family of hormones and their receptors regulates the proliferation and differentiation of many tissue types. Deregulation of this network is a significant factor in the genesis or progression of several human cancers, including neoplasms of the brain, lung, breast, ovary, pancreas and prostate^[1,2]. These observations have spurred efforts to elucidate how this signaling network is regulated and coupled to physiologic responses, and how regulation and coupling are disrupted in malignancies.

Efforts to characterize this signaling network have also been triggered by the observations that the EGF family peptides called neuregulins (NRGs), play a significant role in neural development and function. Neurons produce NRGs, while post-synaptic cells or cells associated with neurons (glia or Schwann cell precursors) express ErbB family receptors. NRG activates these receptors through a paracrine or juxtacrine mechanism. For example, NRGs produced by motor neurons induce acetylcholine receptor subunit transcription and protein synthesis in post-synaptic muscle cells, which express ErbB2 and ErbB3 and possibly EGFR and ErbB4^[3]. Furthermore, NRGs expressed from sensory neuron axons stimulate Schwann cell proliferation and may promote the differentiation of neural crest cells into Schwann cell precursors^[4]. In general, patterns of ErbB3 and ErbB4 expression differ during neural development, suggesting that these NRG receptors couple to distinct signaling pathways and cellular responses^[3]. Additional functions for NRGs have been identified in mutants in which NRG signaling is disrupted^[5-8]. Such mutants display defects in the peripheral nervous system, most notably a loss of cells in the cranial sensory ganglia or a mis-innervation of rhombomeres by cranial sensory and motor neurons. Again, because multiple ErbB family receptors appear to be NRG effectors, there is

significant interest in how these receptors couple to distinct signaling effectors and biological function.

A. EGF Family Hormones

There are at least eight different hormones in the EGF family: EGF itself, Transforming Growth Factor alpha (TGF α); Heparin-binding Epidermal Growth Factor-like Factor (HB-EGF); Amphiregulin (AR), also known as Keratinocyte Autocrine Factor or Colorectal-Cell Derived Growth Factor; Epiregulin (EPR); Betacellulin (BTC); the Neuregulins (NRGs), also known as Heregulins, Neu Differentiation Factors, Glial Growth Factors, Acetylcholine Receptor Inducing Activity, or Sensory and Motor Neuron-Derived Factor; and the Neuregulin2s (NRG-2s), also known as the Cerebellum-Derived Growth Factors. Moreover, multiple NRG and NRG-2 isoforms arise from alternative transcriptional splicing^[1-4,9-11].

Most EGF family peptides are synthesized as transmembrane precursors that can be proteolytically cleaved to release the soluble form of the hormone, or can function as membrane-anchored hormones in juxtacrine signaling. The soluble hormones can be as small as 50 amino acids, sharing a domain of homology that encompasses approximately 50 amino acids. The salient feature of this domain is six characteristically-spaced cysteine residues that form three intramolecular disulfide linkages and define a three-loop secondary structure^[2]. This domain is both required and sufficient for ErbB family receptor binding and activation; little is known about the physiological functions of the non-EGF homologous domains, which can be extensive.

Two additional proteins share limited homology with EGF family hormones. Cripto-1^[12,13] and Cryptic^[14] contain the six cysteine residues

characteristic of EGF family hormones. However, the spacing of these residues is altered such that Cripto-1, and Cryptic completely lack the "A-loop" formed by the residues between the first and second cysteine residues, and the "B-loop" formed by the residues between the third and fourth cysteine residues is considerably smaller than this domain in other EGF family hormones. Indeed, the synthetic EGF homology domain of Cripto-1 does not activate ErbB family receptors^[15].

B. ErbB Family Receptors

There are four ErbB family receptors: Epidermal Growth Factor Receptor (EGFR - also called HER; ErbB)^[16]; ErbB2 (also Neu, HER-2)^[17,18]; ErbB3 (HER3)^[19,20]; and ErbB4 (HER4)^[21]. The human forms of these receptors range in size from 1210 to 1343 amino acids. They each consist of a cysteine-rich extracellular domain, a single membrane-spanning domain, and a large cytoplasmic domain composed of a tyrosine kinase domain and several tyrosine residues that are phosphorylated upon receptor activation. Ligand binding stimulates receptor dimerization and tyrosine phosphorylation at several sites that then serve to dock effector proteins and couple to physiologic responses.

III. Differential Activation and Coupling of ErbB Family Receptors

A. Differential Activation of ErbB Family Receptors

A number of mechanisms contribute to the complexity and interconnectedness of the EGF family/ErbB family signaling network. These include the large number of ligands and extensive cross-interactions among the receptors.

1. *A single EGF family hormone can bind multiple receptors.* For example, BTC, HB-EGF, and EPR activate both the EGF receptor and ErbB4, while NRG and NRG-2 both bind ErbB3 and ErbB4 (Fig. 1).

2. *A single ErbB family receptor can bind multiple hormones.* With the exception of ErbB2, which is an orphan receptor, each ErbB family receptor binds multiple hormones. EGF, TGF α , HB-EGF, AR, BTC, and EPR bind to the EGFR. BTC, NRG, NRG-2, HB-EGF, and EPR bind ErbB4, but only NRG and NRG-2 bind ErbB3 (Fig. 1).

3. *There are three distinct functional groups of EGF family hormones.* These groups are distinguished by their abilities to bind to and activate distinct sets of individual receptors (Fig. 1). The first group consists of EGF and its functional analogs TGF α , and AR, which all bind and activate EGFR but not the other receptors. The second group consists of NRG and NRG-2, which bind ErbB3 and ErbB4. The third group consists of BTC, EPR, and HB-EGF. These hormones bind and activate both EGFR and ErbB4.

4. *EGF family hormones can activate receptors in trans.* Receptors that do not bind a particular hormone when expressed alone can be cross-activated ("transmodulated") if a binding-competent receptor is also present. For example, although EGF does not bind to or activate ErbB2 expressed by itself, EGF induces the tyrosine phosphorylation of both EGFR and ErbB2 in cells expressing both

receptors^[22-24] (Figure 1). Furthermore, even a kinase-inactive ErbB2 mutant can be cross-activated by EGF and EGFR^[25]. Since the transmodulation of ErbB2 by the EGFR is accompanied by the formation of EGF-stimulated EGFR-ErbB2 heterodimers^[26-27], it is likely that the kinase responsible for ErbB2 transmodulation is the EGFR itself. Nonetheless, a plausible alternative is that a *src*-family kinase activated by the EGFR is involved^[28].

Analogous heterotypic interactions are now known to occur extensively among other combinations of ErbB family receptors (Fig. 1). The presence of a single hormone-binding receptor is generally sufficient for EGF family hormones to activate all other ErbB family members present. However, RTKs outside the ErbB receptor family do not cross-activate these receptors, nor can they themselves be activated *in trans* by EGF family hormones and ErbB family receptors. There are two notable exceptions: While BTC activates ErbB4, BTC does not activate ErbB3 in cells expressing both ErbB3 and ErbB4 (Fig. 1)^[29]. Similarly, while NRG α binds ErbB3, it does not activate either EGFR or ErbB3 in cells expressing these receptors^[30].

At a more quantitative level, there is a graded hierarchy of heteromeric interactions that may reflect differences in affinities of the various hormone-receptor-receptor complexes. For example, EGF, which binds only the EGFR, transmodulates ErbB2 more strongly than ErbB3 or ErbB4. Similarly, NRG β , which binds ErbB3 and ErbB4, transmodulates ErbB2 more strongly than EGFR. This suggests that ErbB2 is the preferred target for transmodulation by a ligand-activated ErbB family receptor^[31-33].

Since many cell types express at least three of the four receptors, this implies that there is competition among receptors for dimerization partners. This may explain the finding that pretreatment with NRG inhibits subsequent EGF binding, suggesting that recruitment of the EGFR into complexes with ErbB3

or ErbB4 reduces the availability of free EGFR^[34]. Moreover, transmodulation of the EGFR in T47D cells by NRG (via ErbB3 and ErbB4) is enhanced when ErbB2 is selectively removed^[33]. However, a simple competition model does not account for the observation that downregulation of ErbB2 *reduces* ErbB4 transmodulation by EGF (and the EGFR)^[33].

The mechanism and stoichiometry of heteromeric receptor interactions have not been determined, and reflects the absence of a basic understanding about receptor oligomerization. For example, it is possible that higher order oligomers rather than dimers are the active signaling species. Furthermore, it is not known if a ligand binds to one or both receptors in a heterotypic receptor complex. Co-expression of binding and non-binding ErbB family members in some cases enhances hormone binding affinity^[35], while intracellular retention of ErbB2 reduces EGF and NRG binding by accelerating their dissociation^[36]. (We use "binding" and "non-binding" here to denote the behavior of the receptors when expressed individually.) The means by which a non-binding receptor is recruited into a receptor complex and can modulate ligand binding affinity are uncertain. Hypothetically, in EGFR/ErbB2 transmodulation, EGF binding may unveil a cryptic EGFR/ErbB2 inter-receptor binding site, and/or may stabilize EGF binding to ErbB2. Similarly, formation of EGFR-ErbB2 dimers may alter the conformation of the ErbB2 hormone binding domain or create a composite binding site encompassing elements from both receptors. EGF appears to bind the EGFR with a 1:1 stoichiometry^[37,38] and it has been proposed that EGF binds bivalently, with each EGF molecule binding to a high affinity site on one EGFR molecule and a low affinity site on another EGFR molecule^[38]. Bivalent hormone binding is consistent with the observation that BTC and EGF-NRG chimeras bind both EGFR and ErbB4^[29,39]. It has been proposed that hormone binding to the high affinity binding site is required to stabilize receptor dimers

and for receptor activation. Therefore, bivalent binding of a hormone molecule to a high affinity site on one receptor ("binding receptor) and a lower affinity site on a heterotypic ErbB family receptor molecule ("non-binding" receptor) may be the mechanism underlying receptor heterodimerization and transmodulation. Differences in the affinity of this "lower affinity" binding site on the "non-binding" receptor may explain the variable heterodimerization and transmodulation potential for the four ErbB family receptors. And finally, these possibilities mean that co-expression of ErbB family receptors may create novel "emergent" binding specificities.

Intriguing observations that have led to a greater understanding of ErbB family receptor heterodimerization are that NRG induces the formation of EGFR-Neu heterodimers and that this heterodimerization is blocked by the Neu tyrosine kinase inhibitor tyrphostin AG879. Ligand-induced ErbB family receptor dimers apparently dissociate and can nucleate "secondary" (hetero)dimerization with additional receptor molecules. Moreover, receptor phosphorylation is apparently required for dissociation of the "primary" receptor dimers and for formation of "secondary" heterodimers^[40]. Because receptor phosphorylation also triggers receptor internalization and degradation, the amount of receptor heterodimerization must be regulated by a number of factors, including hormone and receptor concentration, the affinity for receptor dimerization, receptor kinase activity, and rate of receptor internalization.

5. *ErbB3 requires a partner.* A special case is the reliance of ErbB3 signaling on heteromeric interactions. Four residues in the ErbB3 tyrosine kinase homology domain diverge from the consensus tyrosine kinase sequence^[20,41], and ErbB3 has little or no associated kinase activity^[41]. Although ErbB3 expressed alone binds NRGs, tyrosine phosphorylation of this receptor only occurs in the

presence of additional ErbB family members. Presumably, they are required for cross-phosphorylation of ErbB3^[29,35,36,42,43].

B. Coupling of ErbB Family Receptors to Biological Responses and Signaling Effectors

The complex regulation of ErbB family receptor activation is significant because the four receptors couple to distinct sets of signaling effectors and biological responses.

1. *ErbB family receptors have different signaling specificities.* Each receptor has unique signaling specificities, as first suggested by the unique hormone-independent transforming activity of overexpressed ErbB2 relative to the other receptors^[44-51]. These differences reflect differential activation of signaling pathways, as was first shown to occur for EGFR and ErbB2^[46,52].

2. *ErbB family receptor heterodimerization diversifies biological responses.* An early indication that activation of multiple ErbB family receptors increases response diversity was the finding that EGFR and ErbB2 synergize in transformation of NR6 fibroblasts^[53]. Similarly, a subset of receptor combinations promotes hormone-independent or NRG-dependent transformation of NIH3T3 cells^[48,49,51]. Interleukin 3 (IL3) -independent survival or proliferation of a panel of Ba/F3 cells with defined receptor content depends upon the specific combinations of receptors activated (Fig. 2). In this cell background, activation of ErbB4 alone yields no measurable response while activated EGFR couples to IL3-independent survival. However, activation of EGFR and ErbB4 together leads to IL3-independent proliferation^[29,43]. Conversely, selective intracellular retention (and inactivation) of ErbB2 in T47D cells radically diminishes the extent and duration of MAP kinase activation by

EGF and NRG, suggesting that MAP kinase is predominantly coupled to ErbB2 activated by transmodulation^[36].

The simplest interpretation for receptor cooperativity in induction of biological responses is that different receptors activate complementary signaling pathways. However, an alternative explanation is that receptor heteromers have unique signaling specificities. This is plausible, since in a cross-phosphorylation reaction within a heterodimer, the identity and geometry of kinase/substrate pairs differ from that for a homodimer. In NIH3T3 cells ectopically expressing EGFR and ErbB3, NRG stimulates anchorage-independent growth, while EGF does not, despite the fact that EGF stimulates higher levels of receptor phosphorylation than NRG. Furthermore, EGF treatment mobilizes intracellular Ca^{2+} stores, while NRG treatment does not^[51]. Similarly, when the EGFR is activated by HB-EGF in a breast tumor cell line, the downstream signaling effector Cbl is tyrosine phosphorylated and complexes with the EGFR. However, when EGFR is activated by NRG through transmodulation by ErbB3 or ErbB4, Cbl is not tyrosine phosphorylated nor does it complex with the EGFR, despite the fact that HB-EGF and NRG stimulate similar levels of EGFR phosphorylation^[33]. These data suggest that distinct sets of receptor tyrosine residues become phosphorylated in response to different stimuli, resulting in differential coupling to signaling effectors and biological responses.

3. ErbB family receptors couple to distinct cellular signaling effectors.

Although it is clear that ErbB family receptors differentially couple to biological responses the specific substrates and pathways associated with these different responses have not been elucidated. A number of receptor effectors have been identified, a few of which may be receptor-specific^[1,31,36,46,52,54-59]. For example, Cbl is activated by and complexes with the EGFR but not the other ErbB family

receptors^[60]. Similarly, the CHK Csk-homologous kinase binds to ErbB2, but does not bind EGFR, ErbB3, or ErbB4^[61].

IV. Conclusions

Emerging evidence demonstrates that the extensive cross-interactions revealed by tissue culture analysis of the EGF system has profound importance *in vivo*. This is manifested by the striking phenotypic similarities of mice with homozygous disruptions of the ErbB2, ErbB4, and NRG genes^[5-8]. These three gene disruptions are all embryonically lethal at day 10.5 post coitum and induce overlapping but not identical defects in the nervous system. Significantly, these animals all lack the trabecular extensions of the ventricular myocardium, which results in lethality due to cardiac malfunction. ErbB2 and ErbB4 are expressed in the myocardium, while NRG is expressed in the endocardium. The disruption phenotypes show that paracrine activation of both ErbB2 and ErbB4 by NRG is required for proper myocardial development and verifies the importance of transmodulation of ErbB2 in a physiologic response to NRG^[4,62].

A number of open questions regarding the regulation and coupling of this signaling network remain. For the hormones, there is little understanding of the role of the non-EGF homologous domains, which can be quite large and contain a number of recognizable motifs. For example, some of the differentially-spliced NRG isoforms include an immunoglobulin (Ig)-like domain, a glycosylation-rich spacer domain, a cysteine-rich "sensory and motor neuron-derived factor" domain, and a variant kringle domain^[9,63]. While these domains are not required for activation of ErbB3 or ErbB4, they may regulate hormone-receptor interactions in a quantitative manner. In fact, mutant mice homozygous for a mutant NRG gene containing a disruption in the Ig-like domain die during embryogenesis and exhibit neurologic and cardiac defects

similar to those observed in mice homozygous for complete disruption of the NRG gene^[5,8]. While this implies that the Ig-like domain is required for ErbB family receptor activation, another possibility is that this domain is required for NRG stabilization or presentation by extracellular matrix *in vivo*. In a similar vein, only a little more is known about regulation of hormone-receptor interactions by heparin-sulfate proteoglycans (HSPGs). NRG, HB-EGF, and AR bind HSPGs, and HSPGs regulate the interactions of HB-EGF and AR with the EGFR^[64]. HSPGs may regulate ligand binding by acting as low affinity receptors for AR and HB-EGF, increasing the local concentration of these hormones.

EGF family hormones are initially synthesized as membrane-anchored precursors that are subsequently cleaved to release soluble hormone. Experiments using mice homozygous for disruptions in the ErbB4 and NRG genes suggest that activation of ErbB family receptors by membrane-anchored hormones on an adjacent cell or tissue (juxtacrine regulation) is required for some developmental processes. It is unclear, however, whether the membrane-anchored and soluble forms of EGF family hormones stimulate identical patterns of receptor tyrosine phosphorylation. Steric and conformational constraints on the membrane-anchored hormones might restrict their activities. Several of the membrane-anchored hormone precursors possess significant cytoplasmic tails. During juxtacrine receptor activation the membrane-anchored hormones may also act as receptors, coupling to signaling effectors and physiologic changes in response to ErbB family receptor binding. This possibility has stimulated efforts to identify proteins that interact with the cytoplasmic domains of EGF family prohormones. The cytoplasmic domain of TGF α has been shown to associate with an uncharacterized protein kinase activity as well as a p86 cytoplasmic protein. However, the identities of the protein kinase and the p86 cytoplasmic

protein have yet to be determined and the regulation of these interactions has yet to be defined^[65-66].

Another emerging field of study is the role of ErbB family receptors as effectors for stimuli independent of EGF family hormones ^[67], much as non-receptor protein tyrosine kinases serve as signaling effectors for receptors lacking kinase activity. Treatment of HeLa cells with short-wavelength ultraviolet light (UVC) stimulates EGFR and p42 MAP kinase phosphorylation and induces *c-fos* and *c-jun* transcription. These responses are not seen in HeLa cells ectopically expressing a dominant-negative EGFR mutant^[68]. It has been proposed that one mechanism by which UV induces cellular responses is through the induction of reactive oxygen species (ROS), such as hydrogen peroxide. Therefore, it is not surprising that in vascular smooth muscle cells hydrogen peroxide also stimulates the phosphorylation of EGFR and MAP kinases as well as the formation of complexes containing Shc, Grb2, SOS, and EGFR^[69]. Surprisingly, EGF stimulates hydrogen peroxide generation in A431 human carcinoma cells, and eliminating hydrogen peroxide with catalase reduces EGFR tyrosine phosphorylation in response to EGF. It has been proposed that hydrogen peroxide inhibits a protein phosphatase specific for the EGFR and that this inhibition is required for the maintenance of EGFR in its phosphorylated state^[70]. Therefore, cellular stress, which in some cases is accompanied by ROS release, may be coupled to the MAP kinase signaling pathway through EGFR and perhaps other ErbB family receptors as well.

There is also increasing evidence that G-protein-coupled serpentine receptors (GPCR) also regulate ErbB family receptor signaling. The GPCR ligands thrombin, endothelin-1, and lysophosphatidic acid all activate Neu, EGFR, Shc, Grb2, and the ERK1 and ERK2 MAP kinases in Rat-1 fibroblasts. Furthermore, activation of these signaling pathways by GPCR ligands is disrupted in Rat-1 cells

expressing a dominant negative EGFR mutant or in Rat-1 cells pre-incubated with the EGFR antagonist tyrphostin AG1478^[71]. The mechanism for ErbB family receptor phosphorylation in response to GPCR ligands is still unclear, although it has been proposed that src family kinases may be involved. An interesting twist is that the purified EGFR phosphorylates the $G_{s\alpha}$ subunit of the heterotrimeric G protein complex *in vitro* and that phosphorylated $G_{s\alpha}$ displays increased GTPase activity and greater GTP γ S binding capacity and that phospho- $G_{s\alpha}$ augmented adenyl cyclase activity in S49 cyc⁻ cell membranes^[72-73]. Since EGF stimulates cAMP accumulation in the heart via $G_{s\alpha}$ ^[72] cross-talk between ErbB family receptors and the GPCR signal transduction pathway may be bidirectional.

Acknowledgments

We apologize to many authors for omitting references to their work due to restrictions on the length of the review and on reference numbers. This work was supported in part by National Cancer Institute, United States Public Health Service Grant CA-45708 and by United States Army Medical Research and Materiel Command Grant DAMD-17-94-J-4476 to D.F.S. D.R. was supported by the National Cancer Institute, USPHS Postdoctoral Training Grant HD-07149 and by a United States Army Medical Research and Materiel Command Postdoctoral Fellowship DAMD-17-94-J-4036. We also acknowledge the assistance and generosity of our collaborators, who are too numerous to mention by name.

Figure Legends

Figure 1. Three distinct functional groups of EGF family hormones.

The patterns of ErbB family receptor activation stimulated by various EGF family hormones are shown for cell lines expressing ErbB family receptors singly or in pairwise combinations. Where there are quantitative variations within groups, the pattern shown applies to the prototype member listed first. A filled box indicates receptor activation, with the fill darkness indicating the intensity of receptor activation. A white "x" on a filled background indicates that the hormone binds the receptor but does not activate it. Adapted from references 10, 29, 31, 35, 36, 42, 43, 74-83.

Figure 2 - Responses of Recombinant Ba/F3 Cell Lines to ErbB Family Receptor Activation

The patterns of interleukin-3 (IL3) -independent responses stimulated by various EGF family hormones are shown for Ba/F3 cell lines expressing ErbB family receptors singly or in pairwise combinations. A filled box indicates an IL3-independent response, with a gray fill indicating IL3-independent survival and a black fill indicating IL3-independent proliferation. The hormones used to elicit these responses are indicated by name. Adapted from references 29, 43, 80.

References

1. Hynes, N.E., and Stern, D.F. (1994). The biology of erbB2/neu/HER2 and its role in cancer. *Biochim. Biophys. Acta.* **1198**, 165-184.
2. Salomon, D.S., Brandt, R., Ciardiello, F., and Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. *Cr. Rev. Onc. Hematol.* **19**, 183-232.
3. Fischbach, G.D. and Rosen, K.M. (1997). ARIA: A neuromuscular junction neuregulin. *Ann. Rev. Neurosci.* **20**, 429-458.
4. Carraway, K.L. III. (1996). Involvement of the neuregulins and their receptors in cardiac and neural development. *BioEssays* **18**, 263-266.
5. Meyer, D., and Birchmeier, C. (1995). Multiple essential functions of neuregulin in development. *Nature* **378**, 386-390.
6. Gassmann, M., Casagrande, F., Orioll, D., Simon, H., Lai, C., Klein, R., and Lemke, G. (1995). Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. *Nature* **378**, 390-394.
7. Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., and Hauser, C. (1995). Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature* **378**, 394-398.
8. Kramer, R., Bucay, N., Kane, D.J., Martin, L.E., Tarpley, J.E., and Theill, L.E. (1996). Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. *Proc. Natl. Acad. Sci. USA* **93**, 4833-4838.
9. Marchionni, M. A., Goodearl, A. D. J., Chen, M. S., Bermingham-McDonogh, O., Kirk, C., Hendricks, M., Danehy, F., Misumi, D., Sudhalter, J., Kobayashi, K., Wroblewski, D., Lynch, C., Baldassare, M., Hiles, I., Davis, J. B., Hsuan, J. J., Totty, N. F., Otsu, M., McBurney, R. N., Waterfield, M. D., Stroobant, P., & Gwynne, D. (1993). Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. *Nature* **362**, 312-318.

10. Chang, H., Riese, D.J. II, Gilbert, W., Stern, D.F., and McMahon, U.J. (1997). Ligands for ErbB family receptors encoded by a newly-characterized neuregulin-like gene. *Nature* **387**, 509-512.
11. Carraway, K.L. III, Weber, J.L., Under, M.J., Ledesman, J., Yu, N., Gassmann, M., and Lai, C. (1997). Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. *Nature* **387**, 512-516.
12. Ciccodicola, A., Dono, R., Obici, S., Simeone, A., Zollo, M., and M.G. Persico. (1989). Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. *EMBO J.* **8**, 1987-1991.
13. Brandt, R., Normanno, N., Gullick, W.J., Lin, J.H., Harkins, R., Schneider, D., Jones, B.W., Ciardiello, F., Persico, M.G., Armenante, F., Kim, N., and Salomon, D.S. (1994). Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. *J. Biol. Chem.* **269**, 17320-17328.
14. Shen, M.M., Wang, H., and Leder, P. (1997). A differential display strategy identifies cryptic, a novel EGF-related gene expressed in the axial and lateral mesoderm during mouse gastrulation. *Development* **124**, 429-442.
15. Kannan, S., DeSantis, M., Lohmeyer, M., Riese, D.J. II, Smith, G.H., Hynes, N., Seno, M., Brandt, R., Bianco, C., Persico, G., Kenney, N., Normanno, N., Martinez-Lacaci, I., Ciardiello, F., Stern, D.F., Gullick, W.J., and Salomon, D.S. (1997). Cripto enhances the tyrosine phosphorylation of Shc and activates MAP-Kinase in mammary epithelial cells. *J. Biol. Chem.* **272**, 3330-3335.
16. Ullrich, A., Coussens, L., Hayflick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Liebermann, T.A., Schlessinger, J., Downward, J., Mayes, E.L.V., Whittle, N., Waterfield, M.D., and Seeburg, P.H. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* **309**, 418-425.
17. Schechter, A.L., Hung, M.C., Vaidyanathan, L., Weinberg, R.A., Yang-Feng, T.L., Francke, U., Ullrich, A., and Coussens, L. (1985). The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science* **229**, 976-978.

18. Semba, K., Kamata, N., Toyoshima, K., and Yamamoto, T. (1985). A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **82**, 6497-6501.
19. Kraus, M.H., Issing, W., Miki, T., Popescu, N.C., and Aaronson, S.A. (1989). Isolation and characterization of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. *Proc. Natl. Acad. Sci. USA* **86**, 9193-9197.
20. Plowman, G.D., Whitney, G.S., Neubauer, M.G., Green, J.M., McDonald, V.L., Todaro, G.J., and Shoyab, M. (1990). Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. *Proc. Natl. Acad. Sci. USA* **87**, 4905-4909.
21. Plowman, G.D., J.-M. Culouscou, G.S. Whitney, J.M. Green, G.W. Carlton, L. Foy, M.G. Neubauer, and M. Shoyab. (1993). Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. *Proc. Natl. Acad. Sci. USA* **90**, 1746-1750.
22. Stern, D.F., Heffernan, P.A., and Weinberg, R.A. (1986). p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. *Mol. Cell. Biol.* **6**, 1729-1740.
23. Stern, D.F., and Kamps, M.P. (1988). EGF-stimulated tyrosine phosphorylation of p185^{neu}: a potential model for receptor interactions. *EMBO J.* **7**, 995-1001.
24. King, C.R., Borrello, I., Bellot, F., Comoglio, P., and Schlessinger, J. (1988). EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. *EMBO J.* **7**, 1647-1651.
25. Connelly, P.A. and Stern, D.F. (1990). The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine kinase cascade. *Proc. Natl. Acad. Sci. USA* **87**, 6054-6057.

26. Goldman, R., Ben Levy, R., Peles, E., and Yarden, Y. (1990). Heterodimerization of the ErbB1 and ErbB2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation. *Biochemistry* 29, 11024-11028.
27. Wada, T., Qian, X., and Greene, M.I. (1990). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. *Cell* 61, 1339-1347.
28. Muthuswamy, S.K., and Muller, W.J. (1995). Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. *Oncogene* 11, 271-279.
29. Riese, D.J. II, Bermingham, Y., van Raaij, T.M., Buckley, S., Plowman, G.D., and Stern, D.F. (1996). Betacellulin activates the epidermal growth factor receptor and ErbB4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin- β . *Oncogene* 12, 345-353.
30. Pinkas-Kramarski, R., Shelly, M., Glathe, S., Ratzkin, B., and Yarden, Y. (1996). Neu differentiation factor/Neuregulin isoforms activate distinct receptor combinations. *J. Biol. Chem.* 271, 19029-19032.
31. Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B.J., Sela, M., and Yarden, Y. (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. *EMBO J.* 15, 2452-2467.
32. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B.J., and Yarden, Y. (1996). A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. *Mol. Cell. Biol.* 16, 5276-5287.
33. Graus-Porta, D., Beerli, R.R., Daly, J.M., and Hynes, N.E. (1997). ErbB2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling. *EMBO J.* 16, 1647-1655.
34. Karunagaran, D., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. (1995). Neu differentiation factor inhibits EGF binding. *J. Biol. Chem.* 270, 9982-9990.

35. Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., Fendly, B.M., Cerione, R.A., Vandlen, R.L., and Carraway, K.L. III. (1994). Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. *J. Biol. Chem.* 269, 14661-14665.
36. Karunagaran, D., Tzahar, E., Beerli, R., Chen, X., Graus-Porta, D., Ratzkin, B.J., Seger, R., Hynes, N.E., and Yarden, Y. (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. *EMBO J.* 15, 254-264.
37. Sherill, J.M., and Kyte, J. (1996). Activation of epidermal growth factor receptor by epidermal growth factor. *Biochem.* 35, 5705-5718.
38. Lemmon, M.A., Bu, Z., Ladbury, J.E., Zhou, M., Pinchasi, D., Lax, I., Engelman, D.M., and Schlessinger, J. (1997). Two EGF molecules contribute additively to stabilization of the EGFR dimer. *EMBO J.* 16, 281-294.
39. Barbacci, E.G., Guarino, B.C., Stroh, J.G., Singleton, D.H., Rosnack, K.J., Moyer, J.D., and Andrews, G.C. (1995). The structural basis for the specificity of epidermal growth factor and heregulin binding. *J. Biol. Chem.* 270, 9585-9589.
40. Gamett, D.C., Pearson, G., Cerione, R.A., and Friedberg, I. (1997). Secondary dimerization between members of the epidermal growth factor receptor family. *J. Biol. Chem.* 272, 12052-12056.
41. Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L. III. (1994). Insect cell-expressed p180^{erbB3} possesses an impaired tyrosine kinase activity. *Proc. Natl. Acad. Sci. USA* 91, 8132-8136.
42. Carraway, K.L. III, Sliwkowski, M.X., Akita, R., Platko, J.V., Guy, P.M., Nuijens, A., Diamonti, A.J., Vandlen, R.L., Cantley, L.C., and Cerione, R.A. (1994). The erbB3 gene product is a receptor for heregulin. *J. Biol. Chem.* 269, 14303-14306.
43. Riese, D.J. II, van Raaij, T.M., Plowman, G.D., Andrews, G.C., and Stern, D.F. (1995). The cellular response to neuregulins is governed by complex interactions of the ErbB receptor family. *Mol. Cell. Biol.* 15, 5770-5776.

44. Hudziak, R.M., Schlessinger, J., and Ullrich, A. (1987). Increased expression of the putative growth factor receptor p185^{HER2} causes transformation and tumorigenesis of NIH3T3 cells. *Proc. Natl. Acad. Sci. USA* **84**, 7159-7163.
45. DiFiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., and Aaronson, S.A. (1987b). ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. *Science* **237**, 179-182.
46. DiFiore, P.P., Segatto, O., Lonardo, F., Fazioli, F., Pierce, J.H., and Aaronson, S.A. (1990). The carboxyl-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. *Mol. Cell. Biol.* **10**, 2749-2756.
47. Segatto, O., Lonardo, F., Wexler, D., Fazioli, F., Pierce, J.H., Bottaro, D.P., White, M.F., and DiFiore, P.P. (1991). The juxtamembrane regions of the epidermal growth factor receptor and gp185^{erbB2} determine the specificity of signal transduction. *Mol. Cell. Biol.* **11**, 3191-3202.
48. Alimandi, M., Romano, A., Curia, M.C., Muraro, R., Fedi, P., Aaronson, S.A., DiFiore, P.P., and Kraus, M.H. (1995). Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. *Oncogene* **10**, 1813-1821.
49. Zhang, K., Sun, J., Liu, N., Wen, D., Chang, D., Thomason, A., and Yoshinaga, S.K. (1996). Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. *J. Biol. Chem.* **271**, 3884-3890.
50. Cohen, B.D., Green, J.M., Foy, L., and Fell, H.P. (1996). HER4-mediated biological and biochemical properties in NIH3T3 cells. *J. Biol. Chem.* **271**, 4813-4818.
51. Cohen, B.D., Kiener, P.A., Green, J.M., Foy, L., Fell, H.P., and Zhang, K. (1996). The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. *J. Biol. Chem.* **271**, 30897-30903.
52. Fazioli, F., Kim, U.-H., Rhee, S.G., Molloy, C.J., Segatto, O., and DiFiore, P.P. (1991). The erbB2 mitogenic signaling pathway: Tyrosine phosphorylation of phospholipase C- γ and

GTPase activating protein does not correlate with erbB2 mitogenic potency. *Mol. Cell. Biol.* **11**, 2040-2048.

53. Kokai, Y., Myers, J.N., Wada, T., Brown, V.I., LeVea, C.M., Davis, J.G., Dobashi, K., and Greene, M.I. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. *Cell* **58**, 287-292.
54. Carter, T.H., and Kung, H.J. (1994). Tissue specific transformation by oncogenic mutants of epidermal growth factor receptor. *Crit. Rev. Oncogen.* **5**, 389-428.
55. van der Geer, P., Hunter, T., and Lindberg, R.A. (1994). Receptor protein-tyrosine kinases and their signal transduction pathways. *Ann. Rev. Cell Biol.* **10**, 521-337.
56. Kumar, V., Bustin, S.A., and McKay, I.A. (1995). Transforming growth factor alpha. *Cell Biol. Intl.* **19**, 373-388.
57. Hunter, T. (1995). Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. *Cell* **80**, 225-236
58. Earp, H.S., Dawson, T.L., Li, X., and Yu, H. (1995) Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. *Br. Cancer Res. Treat.* **35**, 115-132.
59. Bacus, S.S., Yarden, Y., Oren, M., Chin, D.M., Lyass, L., Zelnick, C.R., Kazarov, A., Toyofuku, W., Gray-Bablin, J., Beerli, R., Hynes, N.E., Nikiforov, M., Haffner, R., Gudkov, A., and Keyomarsi, K. (1996). Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. *Oncogene* **12**, 2535-2547.
60. Levkowitz, G., Klapper, L.N., Tzahar, E., Freywald, A., Sela, M., and Yarden, Y. (1996). Coupling of the c-Cbl protooncogene product to ErbB1/EGF receptor but not to other ErbB proteins. *Oncogene* **12**, 1117-1125.
61. Zrihan-Licht, S., Lim, J., Keydar, I., Sliwkowski, M.X., Groopman, J.E., and Avraham, H. (1997). Association of Csk-homologous Kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. *J. Biol. Chem.* **272**, 1856-1863.


62. Marchionni, M.A. (1995). Neu tack on neuregulin. *Nature* **378**, 334-335.
63. Lemke, G. (1996). Neuregulins in development. *Mol. Cell. Neurosci.* **7**, 247-262.
64. Cook, P.W., Ashton, N.M., Karkaria, C.E., Siess, D.C., and Shipley, G.D. (1995). Differential effects of a heparin antagonist (hexadimethrine) or chlorate on amphiregulin, basic fibroblast growth factor, and heparin-binding EGF-like growth factor activity. *J. Cell. Physiol.* **163**, 418-429.
65. Shum, L., Reeves, S.A., Kuo, A.C., Fromer, E.S., and Derynck R. (1994). Association of the transmembrane TGF-alpha precursor with a protein kinase complex. *J. Cell Biol.* **125**, 903-916.
66. Shum, L., Turck, C.W., and Derynck, R. (1996). Cysteines 153 and 154 of transmembrane transforming growth factor-alpha are palmitoylated and mediate cytoplasmic protein association. *J. Biol. Chem.* **271**, 28502-28508.
67. Weiss, F.U., Daub, H., and Ullrich, A. (1997). Novel mechanisms of RTK signal generation. *Curr. Opin. Genet. Dev.* **7**, 80-86.
68. Sachsenmaier, C., Radler-Pohl, A., Zinck, R., Nordheim, A., Herrlich, P., and Rahmsdorf, H.J. (1994). Involvement of growth factor receptors in the mammalian UVC response. *Cell* **78**, 963-972.
69. Rao, G.N. (1996). Hydrogen peroxide induces complex formation of Shc-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. *Oncogene* **13**, 713-719.
70. Bae, Y.S., Kang, S.W., Seo, M.S., Baines, I.C., Tekle, E., Chock, P.B., and Rhee, S.G. (1997). Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. *J. Biol. Chem.* **272**, 217-221.
71. Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. (1996). Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. *Nature* **379**, 557-560.

72. Nair, B.G., Parikh, B., Milligan, G., and Patel, T.B. (1990). $G_{s\alpha}$ mediates epidermal growth factor-elicited stimulation of rat cardiac adenylate cyclase. *J. Biol. Chem.* **265**, 21317-23122.
73. Poppleton, H., Sun, H., Fulgham, D., Bertics, P., and Patel, T.B. (1996). Activation of $G_{s\alpha}$ by the epidermal growth factor receptor involves phosphorylation. *J. Biol. Chem.* **271**, 6947-6951.
74. Shoyab, M., Plowman, G.D., McDonald, V.L., Bradley, J.G., and Todaro, G.J. (1989). Structure and function of human amphiregulin: A member of the epidermal growth factor family. *Science* **243**, 1074-1076.
75. Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C., and Klagsbrun, M. (1991). A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. *Science* **251**, 936-939.
76. Johnson, G.R., Kannan, B., Shoyab, M., and Stromberg, K. (1993). Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185^{erbB2}. *J. Biol. Chem.* **268**, 2924-2931.
77. Plowman, G.D., Green, J.M., Culouscou, J.-M., Carlton, G.W., Rothwell, V.M., and Buckley, S. (1993). Heregulin induces tyrosine phosphorylation of Her4/p180^{erbB4}. *Nature* **366**, 473-475.
78. Shing, Y., Christofori, G., Hanahan, D., Ono, Y., Sasada, R., Igarashi, K., and Folkman, J. (1993). Betacellulin: A mitogen from pancreatic β cell tumors. *Science* **259**, 1604-1607.
79. Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and Hanada, K. (1995). Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. *J. Biol. Chem.* **270**, 7495-7500.
80. Riese, D.J. II, Kim, E.D., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, G.D., and Stern, D.F. (1996). The epidermal growth factor receptor couples transforming growth factor- α , heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB3, and ErbB4. *J. Biol. Chem.* **271**, 20047-20052.

81. Beerli, R.R., and Hynes, N.E. (1996). Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. *J. Biol. Chem.* **271**, 6071-6076.
82. Elenius, K., Paul, S., Allison, G., Sun, J., and Klagsbrun, M. (1997). Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. *EMBO J.* **16**, 1268-1278.
83. Riese, D.J. II, Komurasaki, T., Plowman, G.D., and Stern, D.F. Activation of ErbB4 by the bifunctional EGF family hormone epiregulin is regulated by ErbB2. Submitted.

Group 1

EGF, TGF α ,
AR



Group 2

NRG, NRG-2




Group 3

BTC, EPI,
HB-EGF



Group 1

EGF, TGF α ,
AR



Group 2

NRG, NRG-2



Group 3

BTC, EPI,
HB-EGF

